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1 Introduction 
1.1 The NF-κB/Rel family 
The Nuclear factor-κB was first characterized by Ranjan Sen and David Baltimore. 
They observed that a factor from nuclear extracts of B-cells binds to the eleven base 
pair long sequence (GGGGACTTTCC) of the κ light chain enhancer [194]. Later, it 
became clear that NF-κB is present in various types of cells. The nuclear factor is not 
a single protein, but consists of two of five different subunits, which form dimers. 
Characteristic for these subunits is the Rel homology domain (RHD) named after the 
homolog oncoprotein v-Rel. This domain contains a DNA binding site as well as an 
interaction / dimerization region and a nuclear localization signal (NLS) [76]. 
Furthermore, the subunits divide into two groups: One with a transcription activation 
domain (TAD) and one without. The proteins RelA (p65), RelB and c-Rel contain a 
transcription activation domain [23, 33, 183, 189, 191, 192], while NF-κB1 (p50) 
and NF-κB2 (p52) do not. The subunits NF-κB1 (p50) and NF-κB2 (p52) are 
translated as precursors named p105 and p100, respectively. These proteins contain 
c-terminal ankyrin repeats similar to the inhibitors of NF-κB (v.i.) [17]. The mature 
NF-κB subunits are produced by proteolytic cleavage in the proteasome [88, 158]. 
The composition of the NF-κB dimer is crucial for its function. So the most common 
heterodimer p50 / p65 works as an enhancer [189] while the homodimers p50 / p50 
and p52 / p52 are repressors of transcription lacking the TAD and competing for 
DNA binding [118]. The inhibitory mechanism is not yet understood. The 
composition of NF-κB is tissue specific. The p50 / p65 heterodimer is ubiquitous, but 
NF-κB2, Rel-B, and c-Rel are expressed specifically in lymphoid cells and tissues 
[30]. All Rel/NF- κB proteins, except RelB, have approximately 25 amino acids N-
terminal to the NLS a potential protein kinase A (PKA) phosphorylation site [160] . 
In case of p65, it is well know that a phosphorylation on this site increases its actitivy 
[226]. 
 
1.2 Inhibitors of NF-κB 
In unstimulated cells the NF-κB dimer is retained in the cytoplasm in an inactive 
state in reason of its association with proteins called inhibitors of NF-κB (IκB) [15]. 
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Today eight inhibitors of NF-κB are characterized: p100, p105, IκB-α, IκB-β, IκB-γ, 
IκB-ε, Bcl-3, IκBδ and IκB-R. The most common members of the IκB family are 
IκB-α and IκB-β with a molecular weights of 37 and 43 kDa. They do not only 
specifically and reversibly inhibit DNA-binding by NF-κB, but also actively 
dissociate DNA-bound NF-κB in vitro [15, 224]. The cloning of this molecules 
revealed that they contain repeated sequences of 30–33 amino acids. These were first 
discovered in the SW16 protein of Saccharomyces cerevisiae and named 
SW16/ankyrin repeats [30, 85]. As described above, the p50 and p52 precursors p105 
and p100 also contain ankyrin repeats in their c-terminal regions and are capable of 
inhibiting NF-κB activity [150, 179]. The c-terminal fragment of p105 is identical to 
IκBγ generated by alternative splicing in lymphocytes and has inhibitory qualities 
[99]. The p100 fragment is named IκBδ [187]. The next member of the IκB family 
IkB-ε stands out by its specificity compared to IκB-α and IκB-β. It apparently only 
binds to c-Rel, RelA, or their respective homodimers [215]. Additionally it is, similar 
to the other two, very important for the nuclear import and export of NF-κB/Rel 
proteins [132]. The other members also have individual qualities: So IκBδ seems to 
predominantly act in the nucleus [220], IκBR interacts with p50 / p65 heterodimers, 
but not with p65 homodimers [177], and the inhibitory nuclear protein Bcl-3 can 
form complexes with p50 and p52 homodimers which are transcriptional activators 
instead of repressors [28, 70, 73]. 
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Figure 1.1: Members of the Rel/NF-κB and IκB families of proteins 
J. Caamaño and C. A. Hunter, Clinical Microbiology Reviews, July 2002, p. 414–429 [35]. 
 
Schematic view of Rel/NF-κB proteins. The arrows indicate the proteolytic 
cleavage sites of p105 and p100 which produce p50 and p52, respectively. Black 
boxes indicate the PEST domains, shaded boxes on Bcl-3 indicate trans-
activation domains, and gray boxes on RelB indicate leucine zipper domains. 
Abbreviations: RHD, Rel homology domain; ANK, ankyrin repeat; P, PKA 
phosphorylation motif, N, nuclear localization site; G, glycine rich region; SS, 
signal-induced phosphorylation sites. 
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1.3 Activation of NF-κB via TNF-α 
The best known pathway for NF-κB activation is the response to TNF-α. TNF 
receptors are expressed on a broad variety of cells. Neurons and glia also express 
TNF receptors [32]. The most important of these receptors for NF-κB activation 
seems to be p55/TNF-R1 [125]. Mice lacking the TNF-R1 in reason of a genetic 
defect show traumatic brain injury with reduced NF-κB activation [32]. The so-
called canonical pathway of NF-κB activation [27, 190] starts with the TNF-α 
binding to the trimerized TNF-R1 and the release of the silencer of death domains 
(SODD/BAG4). This silencer evidently blocks the pathway [104] and it has been 
speculated that this goes along with the recruitment of the heat shock cognate 70 kDa 
(HSC70), a member of the heat shock protein family. BAG4 is known to interact and 
modulate the chaperone activity of HSC70 [31, 198]. The free trimeric death 
domains (DD) of TNF-R1 can afterward function as an assembly platform for 
intracellular interactors which subsequently recruits the adapter protein TNF-R 
associated death domain protein (TRADD), TRAF2/5 and RIP1 [56, 93, 204]. 
Although RIP1 has a kinase activity, this is not important for the signal transduction 
[207]. Instead, it is being polyubiquitinated by the TNF-R associated ubiquitin 
ligases cIAP1 and cIAP2 [22]. This chain does not lead to proteasomal degradation, 
but serves as interaction platform for TGFß-activated kinase binding protein 2 and 3 
(TAB2, TAB3). TAB2 and TAB3 recruit the TGFß-activated kinase (TAK) and 
enables an interaction with the ubiquitin binding domain (UBD) of the NF-kappa-B 
essential modulator NEMO [117]. Furthermore, cIAP1 and cIAP2 ubiquitinate 
themselves and other components of the complex. This enables the association of the 
so-called linear ubiquitin chain assembly complex (LUBAC) which stabilizes the 
signaling complex by additional ubiquitin mediated interactions [22]. The protein  
NEMO is also known as the γ-subunit of the inhibitor of κ B kinase (IKK) complex. 
By bringing NEMO and TAK closely together, TAK can phophorylate and activate 
the IKK subunit β at serines 177 and 181 [53]. The IKK complex is targeted to IκBα 
by its subunit ELKS [63]. The catalytic IKK subunits α and β phosphorylate IκBα at 
serin 32 and 36 so that it can subsequently be ubiquitinated and degraded [6, 58]. The 
free NF-κB e.g. p50 / p65 can now be transported into the nucleus and enhance 
transcription (v.i.). 
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The importance of ubiquitination for NF-κB signaling / complex multimerization is 
also shown by deubiquitinating enzymes such as CYLD which can target NEMO and 
deactivate the IKK complex [127, 208]. Another protein which possesses a 
deubiquitination and ubiquitination activity is A20 which targets RIP [89]. The SCF 
(Skp-1/Cul/F box)-type multisubunit E3 ubiquitin ligase holoenzyme, responsible for 
IκB poly-ubiquitination [222], can also be inhibitied by pyrrolidone dithiocarbamate 
(PDTC) to prevent NF-κB activation [86]. 
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Figure 1.2: Canonical pathway of NF-κB activation by (TNF). 
The activation of the TNF receptor by ligand binding releases SODD and enables the 
binding of TRADD, TRAF2 and RIP1. The TRAF2 associated ubiquitin ligase cIAP 
ubiquitinates RIP1 and itself. The ubiquitination on RIP1 enables the loose association 
of the IKK complex via NEMO and the TAK complex via TAB1/2. The ubiquitination 
on cIAP recruits LUBAC which stabilizes the complex by linear ubiquitin links. This 
proximity leads to the phosphorylation of IKKb by TAK and the IKK complex can 
phosphorylate IkBa, recruited by ELKS, and designate it for degradation. The NLS of 
the NF-kB dimer p50 / p65 is released and NF-kB is transported to the nucleus where 
it can promote the transcription of its targed genes.  
+Ubi=ubiquitination; +PO4
3- 
=phosphorylation. 
Introduction  7 
1.4  Activation of NF-κB by other stimuli 
Besides TNF-α there is a broad variety of other stimuli which induce NF-κB 
activation. This could be for example TNF, LPS, IL-1, NGF or glutamate. These and 
many other stimuli are finally integrated by the IκB kinase complex and culminate in 
NF-κB activation [166]. For example TLRs, as the LPS receptor, are known to use 
two different pathways: The first using a protein called myeloid differentiation 
primary response gene 88 (MyD88) and the second depending on the protein TIR 
domain containing adaptor-inducing interferon-ß (TRIF) [120]. The LPS responding 
receptors TLR2 and TLR4 recruit MyD88. This protein binds to a members of the 
IL-1 receptor-associated kinase (IRAK) family, which interacts with TRAF6. TRAF6 
binds TAB2, TAB3 and TAK1 and the latter phosphorylates and activates the IKK-
complex [3]. The interactions between TRAF6, TAB2, TAB3 and IKK are also 
ubiquitin dependent [44, 117]. 
The signal transduction via TLR3 and TLR4 is TRIF dependent. It is very similar to 
the TNF pathway, in which the proteins TRADD and TRAF2/5 are replaced by TRIF 
and TRAF6, which also bind RIP1 in order to mediate NF-κB activation. As 
described above, TLR4 uses both adaptors, MyD88 and TRIF, whereas TLR3 is the 
only TLR that does not use the MyD88 dependent pathway [120, 219]. 
 
 
1.5 Activation of NF-κB by the non-canonical pathway 
The characteristic of the non canonical pathway is the independence from IKKß and 
NEMO and the dependence on IKKα [51, 195].The non-canonical pathway is used in 
response to ligand binding to the TNF superfamily receptors CD40, RANK, LT-ß-R 
and BAFFR [45, 46, 52]. It is rather important in B cells than in neurons and the 
predominantly activated NF-κB dimer is the p52:RelB heterodimer. The ligand 
binding to LT-ß-R and BAFFR induces the phosphorylation of IKKα by the NF-κB 
inducing kinase (NIK) [136, 137, 178, 211]. IKKα itself phosphorylates p100 [218], 
which is associated with RelB. Phosphorylated p100 is recognized and ubiquitinated 
SCFß-TrCP ubiquitin E3 ligase-complex [7]. The ubiquitination marks the inhibitor for 
processing into the mature subunit p52 by the proteasome [88]. The resulting 
RelB:p52-complexes can translocate to the nucleus and activate NF-κB target genes.  
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1.6 Nuclear import / shuttling 
The free nuclear localization signals of NF-κB dimers is folded into a random coil 
formation, which is able to bind importin. The NLS of p50 and p65 for example are 
recognized by importin α3 and α4 [67]. While importin α4 predominatly recognizes 
the p50 / p65 heterodimer, importin α3 also imports p50 homodimers [67] and 
decreases the constitutional NF-κB activity in this way. The IκB proteins regulate the 
nuclear import by masking the nuclear localizations signal and inducing an alpha 
helical conformation [96]. Herein, the inhibitors show a great specificity: while IκB-
α only interacts with the NLS of p65 only, IκB-β interacts with both the NLS of p50 
and p65 [140]. The alpha helical conformation cannot be recognized by the nuclear 
import receptor importin alpha [102].  
Besides p65, IκBα also contains a NLS which is also masked by interaction with Rel 
proteins [96, 102, 185]. On the one hand, this enables free IκBα to translocate to the 
nucleus and dissociate p50 / p65 heterodimers from DNA [224] and on the other 
hand, it prevents the nuclear import of the trimer. NF-κB is not only imported into 
the nucleus, but also exported. Therefore p65 [75, 95, 206] and IκBα [75, 95, 107, 
139, 206] contain a nuclear export signal (NES), too. This enables the shutteling of 
NF-κB subunits and is most important to silence the signal pathway besides 
promoter-specific degradation of p65 via nuclear proteasomes [184]. 
 
 
1.7 NF-κB in neurons 
Central functions of the nervous system are information transmission, processing and 
storage. Most important for these tissues are two cell types: neurons and glia. While 
neurons receive, transmit and store information, the glia are known as neuronal glue 
(greek glia = glue). They maintain homeostasis and isolate the neurons. Neurons 
communicate via electric and chemical signals with each other. The place where the 
electric signal is converted to a chemical and transferred to a neighbour cell is the 
synapse, consisting of a presynaptic (sending) cell and a postsynaptic (receiving) 
cell. Usually, the presynaptic site is the terminal of an axon and the postsynaptic site 
the terminus of a dendrite. Both are extension of neurons, but axons are mostly 
longer an better isolated and dendtrites are more branched. In many recent 
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publications, learning and memory is connected with the so-called synaptic plasticity 
[182]. The synaptic plasticity describes the efficiency of chemical signal transduction 
by a synapse. This is manly affected by the number of released neurotransmitter and 
the number of specific receptors. 
The participation of NF-κB in synaptic transmission is supported by several studies 
detecting NF-κB in synapses [112, 145, 146]. A second indication for this 
hypothesis, is the fact that a positive correlation between p65 mRNA level and 
synaptic transmission activity was shown [4]. This could be part of a feed forward 
mechanism. In Drosophila melanogaster, the NF-κB homolog Dorsal colocalizes 
with the IκB homolog Cactus in high levels in postsynaptic sites of glutamatergic 
neuromuscular junctions [38]. This substantiates the assumption that NF-κB is used 
as a retrograde messenger to the nucleus. The transport of NF-κB in living neurons 
could be observed using a GFP-tagged p65 after glutamate stimulation [146, 213]. 
Although less is known about the pathway of NF-κB activation in cell of the nervous 
system, it is probable that there is also a Ca
2+
 dependent one because the CAM 
kinase II is reported to activate NF-κB [135, 146]. In two different models, this 
relation is used to create a local p65 knock out in mouse forebrain neurons. Both 
mouse lines show a severe learning deficit. [71, 146]. 
Additionally, NF-κB is an important regulator between neurodegeneration and 
apoptosis or neuroprotective processes including calcium buffering, generation of 
novel synapses, anti-apoptotic gene expression, caspase inhibition, balancing of 
reactive oxygen intermediates, etc. [68, 111, 142, 221]. 
The most frequent heterodimer in the nervous system is p50 / p65 that is either 
constitutively active or forms a complex with the inhibitory subunit IκB-α [16, 79, 
109, 112, 113, 114, 115, 175]. Furthermore, there are κB-binding proteins such as 
brain-specific transcription factor (BETA), specifically detected in grey matter 
extracts [124], developing brain factors (DBFs), which were reported to be highly 
enriched in developing cortex [40], and neuronal κB binding factor (NKBF) with 
different target sequence requirements [157]. These binding factors do not 
exclusively bind to specific genes, but there seems to exist a complex system of 
binding sites, which binds more or less specific one of the transcription factors and 
act together with other binding sites. 
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1.8 NF-κB activating or repressing stimuli in neurons 
TNF-α triggers in a broad variety of cell types related to the nervous system, such as 
neuroblastoma, neurons [18, 110], neuroblastoma [61], astrocytes [199], and 
microglia [133]. It is also reported that TNF-α is able to repress NF-κB activity in 
neurons under certain circumstances [110], e.g. under oxidative stress [77]. Besides 
TNF, there is a broad variety of stimuli, which affect NF-κB activity in the nervous 
system. Many of them are better known for their function in the immune system, like 
interleukins or inflammation mediators. So interleukin-1 is known to induce NF-κB 
in neurons and glia cell [78, 166], interleukin-6 in neurons of the peripheral nervous 
system (PNS) [152], while interleukin-10 reduces the NF-κB activity in astrocytes 
[170], neurons [14] and microglia [64]. The repression of NF-κB activity in 
astrocytes can also be triggered by interleukin-4 [170]. The inflammation mediator 
IFN-γ, which activates T-cells in immune system, can induce NF-κB in microglia in 
combination with beta-amyloid, which is involved in alzheimers disease and 
neuronal signal transduction [26]. In addition, exogene stimuli which affect the 
immune system can influence the NF-κB dependent expression in the nervous 
system. For example, LPS operates as an NF-κB activator in microglia [19] and 
astrocytes [169], whereas aspirin (acetylsalicylic acid) represses NF-κB dependent 
expression in neurons [78]. 
Besides these inflammatory molecules, the cells of the nervous system also respond 
to a lot of growth factors by NF-κB activation or repression. The epidermal growth 
factor (EGF) for example initiates the expression of glutamate transporter 1 (GLT-1) 
in astrocytes via transcription factor NF-κB [225]. The nerve growth factors (NGF) 
triggers NF-κB activation in neurons [101], NGF Schwann cells [39] and 
oligodendrocytes [223], while the brain derived neurotrophic factor (BDNF) 
activates it in microglia [163] and neurons [34]. 
Furthermore, neurotransmitter like glutamate [79] and the related kainate [113] are 
known to signal via induction of NF-κB in neurons and glucocorticoid hormones 
reduce NF-κB dependent expression in neurons [29]. This vast number of stimuli 
emphasizes the importance role of NF-κB in the nervous system. 
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1.9 Neuronal transport of NF-κB 
In most cell types, transcription factors are able to reach their targets by diffusion, in 
contrast to neurons, which neurites could extent far from the cell body. In fact, some 
motor neurons in the human spine could reach a length of more than one meter. For 
these distances, an effective kind of active transport system is needed [92]. For 
intracellular transport, cells have a system of actin filaments and microtubules. [119]. 
The transport on actin filaments is mediated by the motor protein myosin [ 130]. The 
microtubules employ two different motor protein families: The kinesins and dyneins. 
While transport on microtubules is related to long distances, actin transport is 
responsible for short. That means that the cargo is often transferred from one type of 
motor protein to another [94]. Kinesin and dynein are moving in opposite direction 
according to the polarity of the microtubules. Kinesins typically show positive end-
directed movement and dynein drives to the negative ends. In most cells, 
microtubules are oriented with their negative ends near the nucleus and their positive 
ends toward the cell periphery [80]. This is also reported for axons in neurons. 
However, dendrites show this regulation of polarity only near the growth cone, but 
not in their main length [12]. As described above, the NF-kB p50 / p65 heterodimer 
binds to importin. This does not only enable the translocation through the nuclear 
pore complex (NPC), but also delivers associated proteins to the nuclear membrane 
along microtubules via dynein [37,81, 82]. In addition, the retrograde transport of 
NF-κB is dependent on an intact NLS [146, 213]. The dynein dependence of NF-κB 
transport was shown by impeding the transport by overexpression of dynamitin, a 
subunit of the dynein/dynactin motorcomplex [153]. Dynactin is an accessory multi 
protein complex of dynein. It increases the processivity of dynein by the interaction 
of its large subunit p150Glued to the microtubules and dynein. The dynamitin 
subunits connect p150Glued to the cargo-binding domain. This contains a short 
polymer of eight subunits of the actin-related protein Arp1, which is pivotal for 
vesicles binding and other associated polypeptides. The overexpression disturbs the 
formation of the functional complex. An in vitro complex of p50 and p65 and dynein 
could also be detected and disrupted by dynamitin [148, 153]. The transport of p50 
and p65 on microtubules is neuron specific. Microtubule perturbating drugs like 
vincristin have no effect on non neuronal NF-κB transport [154]. Nevertheless, there 
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is little knowledge about interactors in the NF-κB transport. Are there regulators 
specific for NF-κB transport besides the regulation of NF-κB activation? How is this 
specificity generated? What does the transport complex look like? Does dynein 
directly bind importin and importin to NF-κB? To find new NF-κB interactors, a pull 
down experiment with subsequent mass spectrometry analysis is performed in this 
thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: NF-κB activation in the synapse 
Mikenberg, I.; Widera, D.; Kaus, A.; Kaltschmidt, B.; Kaltschmidt, C. PLoS ONE, 2(7):e589 
[153]. 
Schematic presentation for the NF-κB activation in the synapse and its dynein-
mediated microtubule dependent retrograde transport to the nucleus. Neurons 
stimulated by glutamate activate NF- κB by different signaling pathways (e.g. by 
CaMKII). IκB is phosphorylated and subsequently degraded in the proteasome. 
The NLSs of the of NF-κB dimer are unmasked and may bind importin. The 
complex is transported retrogradely towards the nucleus via an association with 
the motor protein dynein/dynactin, where it activates NF-kB target genes. 
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2 Objective of the study 
The neuronal NF-κB transport complex is not yet fully characterized. Besides the 
finding that components like dynein, dynactin, and importin participate in it, a lot of 
questions related to its properties are still unanswered. Particularly, the connection of 
NF-κB to the motor protein is not completely discovered. We assume that unknown 
mediators in an interaction chain between the motor protein (dynein) and the cargo 
(NF-κB) are necessary for their association, responsible for the generation of 
specificity, and targets for regulation. These new interactors are to be found by a 
mass spectrometric analysis of NF-κB complexes, acquired by co-precipitation with 
the NF-κB subunit p65/RelA from neuronal extracts. The interaction of these 
components will be verified and tested for its biologic relevance. This data will help 
to improve our models for neuronal NF-κB transport and may discover new targets 
for the regulation of neuron specific NF-κB signaling. 
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3 Material and methods 
3.1 Computer software 
Biotools      Bruker Daltonics 
Blast 2.2.13     NCBI 
Codon Usage Analyzer 2.0 Morris Maduro 
Excel 2007     Microsoft GmbH 
GIMP 2.6.10     Spencer Kimball, Peter Mattis and      
       the GIMP-developer team 
KEGG      Kanehisa Laboratories 
Mac OS 9.1     Apple Computer, Inc. 
Mascot      Matrix sciences 
MS Office 2007    Microsoft GmbH 
NCBI blast     National Center for Biotechnology Information 
Oligo Calc     Northwestern University 
Primer3      Withhead Institute for Biomedical Research 
Swissprot     Swiss institute of bioinformatics 
Vector NTI     Invitrogen 
Windows 7     Microsoft GmbH 
Windows XP    Microsoft GmbH 
ZEN      Zeiss 
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3.2 Material 
3.2.1 Antibiotics 
Name 
Target  
organism 
Stock conc. 
Effective conc. 
(for selection) 
Ampicillin bacteria 100 mg/mL 50-100 µg/mL 
Chlorampenicol bacteria 35 mg/mL 15 µg/mL 
G418 eukaryotes 100 mg/mL 800 µg/mL (HEK293) 
Kanamycin bacteria 50 mg/mL 50 µg/mL 
Penicillin / Streptomycin bacteria 10000 U/mL 100 U/mL 
Puromycin eukaryotes 10 mg/mL 10 µg/mL 
Streptomycin bacteria 10 mg/mL 100 µg/mL 
Zeocin 
eukaryotes, 
bacteria 
100 mg/mL 
800 µg/mL 
(HEK293), 25 µg/mL 
 
 
3.2.2 Antibodies 
Name Species, type Specificity Supplier for 
Buffer 
conditions 
Dilution 
111-035-
144 
goat, IgG 
H&L HRP 
rabbit 
Jackson 
IRL 
WB PBST 1:4000 
C3956 
rabbit, 
polyclonal 
myc tag SIGMA 
WB, 
IP 
WB blocking 
sol., see IP 
1:4000 (WB), 
1 µg/mL (IP) 
F1804 
(M2) 
mouse, IgG1 Flag tag SIGMA IP see IP 1 µg/mL 
F7425 
rabbit, 
polyclonal 
Flag tag SIGMA WB 
1% BSA in 
PBST 
1:2000 
MOPC21 mouse, IgG1 none SIGMA IP see IP 2-30 µg/rct. 
Sc-371 
(C21) 
rabbit, 
polyclonal 
IgG 
IκBα 
Santa 
Cruz 
WB 
1% BSA in 
PBST 
1:200 
sc-8008 mouse, IgG1 p65 
Santa 
Cruz 
IP see IP 2-30 µg/rct. 
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3.2.3 Bacteria strains 
Strain Genotype 
BL21 DE3 pLysS E. coli B F– dcm ompT hsdS(rB– mB–) gal 
λ(DE3)[pLysS Camr] 
DH5α fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
HB101  F–, thi-1, hsdS20 (rB
–
, mB
–
), supE44, recA13, 
ara-14, leuB6, proA2, lacY1, galK2, rpsL20 
(str
r
), xyl-5, mtl-1 
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(araleu)7697 galU galK rpsL (StrR) endA1 
nupG 
XL1 blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F' proAB lacIqZΔM15 Tn10 
(TetR)] 
 
 
 
3.2.4 Buffers, media, solutions 
All solutions are prepared in water if not described differently. The pH-value is 
adjusted at room temperature with NaOH or HCl if not described differently. 
 
ATP-Stock solution 500 mM ATP PBS 
CaCl2 Solution 
for chemo competent bacteria 
50 mM CaCl2 
DMEM complete DMEM basal medium 
10% FCS 
2 mM glutamine 
2 mM pyruvate 
Penicillin 100 U/mL 
Streptomycin 100 µg/mL 
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dNTPs 10 mM dATP, dCTP, dGTP, dTTP 
each 
ECL Solution A 0.1 M TrisCl pH 8.6 
0.025% luminol 
store at 4°C 
ECL Solution B 0.11% p-coumaric acid in 
DMSO, store dark 
Embedding resin Moviol 
50 mg/mL DABCO 
Fixation solution for microscopy  4% paraformaldehyde in PBS 
Gel extraction solution for MS I 
(flexibilizer extraction solution) 
TFA 0.1% /acetonitrile 60% 
Gel extraction solution for MS II  acetonitrile 50%/H2O 50% 
Gel extraction solution for MS III acetonitrile 50% / NH4HCO3 50 mM 
Gel extraction solution for MS IV acetonitrile 50% / NH4HCO3 10 mM 
Gel extraction solution for MS V 
(trypsinization buffer) 
NH4HCO3 10 mM 
Glycerol solution for bacteria stocks 65 % (v/v) Glycerin 
0.1 MgSO4 
0.025 M Tris Cl, pH 8,0 
GST basic cleaning solution I 100 mM Tris-base 
0.5 M NaCl 
pH 8.5 
GST basic cleaning solution II 100 mM sodium acetate 
0,5 M NaCl 
pH to 4.5 
GST elution buffer 
 
50 mM Tris base 
10 mM glutathione 
0.1 Triton X-100 
pH 8.0 
prepare fresh, store at 4°C 
GST Rigorous cleaning I 6 M guanidine hydrochloride 
GST Rigorous cleaning II 70% ethanol in H2O 
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LB agar LB medium supplemented with 
1.5% agar 
LB medium
 
0.5% yeast extract 
1.0% bacto tryptone 
0.05-1.0% NaCl 
(LB-Lennox 0.5% NaCl) 
Sterilized by autoclav method 
Lysis buffer (for brain extracts) 150 mM NaCl 
50 mM HEPES pH 7,6 
2 mM EGTA 
0.5 % Trition X-100 
1 mM PMSF 
Lysis buffer (for IP after cross link) 50 mM TrisCl, pH 7,5 
150 mM NaCl 
1% NP-40 (v/v), pH 7,5 
Lysis buffer (for IP before cross link) 50 mM HEPES, pH 7,5 
150 mM NaCl 
1% NP-40 (v/v), pH 7,5 
PBS 137 mM NaCl 
2.7 mM KCl 
9.6 mM Na2HPO4 
2.4 mMKH2PO4, pH 7,4 
PBST PBS; 0.05 % (w/v) Tween 20 
Permeabilizing solution 0.25% Triton X-100 in PBS 
SDS-PAGE running buffer 10x 3% Tris base 
14.4% glycine 
0.5% SDS 
SDS loading buffer 4x 0.2 M Tris-Cl pH 6.8 
8 % SDS 
100 mM DTT 
16 % glycerol 
0.01 % Bromphenol blue 
15 mM EDTA 
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SOC medium 1 L 2% tryptone 
0.5% yeast extract 
0.05% NaCl 
2.5 mM KCl 
20 mM glucose 
pH 7.0, sterilized by autoclav method 
TAE-Puffer 40 mM Tris-Acetic acid 
10 mM NaOAc 
1mM Na-EDTA 
pH 7.8 
Transfer buffer I 
(for semi dry blot) 
25 mM Tris 
40 mM aminohexanoic acid 
20 % methanol 
Transfer buffer II 
(for semi dry blot) 
30 mM Tris 
20 % methanol 
Transfer buffer III 
(for semi dry blot) 
300 mM Tris 
20 % methanol 
Tyrode’s buffer 119 mM NaCl 
4.5 mM KCl 
2 mM CaCl2 
0.5 mM MgCl2 
25 mM Glucose 
0.01 mM Glycine 
10 mM Hepes (pH7.33) 
WB blocking solution 5% skimmed milk powder 
in PBS 
WB washing solution 0.5% skimmed milk powder 
in PBST 
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3.2.5 Cell lines 
 
HEK293FT 
The HEK293 cell line is a permanent line established from primary human 
embryonic kidney cells transformed with sheared human adenovirus type 5 DNA 
[84, 128]. The E1A adenovirus gene is expressed in these cells and participates in the 
transactivation of some viral promoters, allowing these cells to produce very high 
levels of protein. The HEK293F cell line is a subclone of HEK293 that was 
originally obtained from Robert Horlick at Pharmacopeia. This subclone captivates 
by its fast growth rate and reduced serum requirements. The HEK293FT cell line 
was produced by transfection of HEK293F with the pCMV-SPORT6TAg.neo 
plasmid [100]. This plasmid carries the SV40 large T antigen gene controlled by the 
human cytomegalovirus (CMV) promoter, which is constitutive and promotes high 
expression levels. The cell line is Gentamycin resistant and a very suitable host for 
lentiviral production [164]. The expression of the neomycin resistance gene in 
HEK293FT cells is controlled by the SV40 enhancer/promoter. 
 
 
3.2.6 Chemicals 
If not noted otherwise, all chemicals were either purchased by Sigma, Roche, Fluka 
or Merck in p.A. Quality. Special chemicals are enlisted here: 
 
10x Taq Puffer #201205       Qiagen 
Acrylamide (30%)/bisacrylamide (8%) solution  Roth 
Agarose           Roth 
APS (ammoniumpersulfate)      Roth 
ATP           SIGMA 
Coomassie brilliant blue G-250     PIERCE 
DABCO           Hoechst 
DMEM Medium         PAA 
DMSO           MERCK 
DNA loading dye (6x)       Fermentas  
DRAQ5           Alexis 
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DSP           Thermo scientific 
Ethanol           VWR International 
Ethidiumbromide         SIGMA 
Gene Ruler DNA Ladder Mix      Fermentas 
Glutathione (reduced)        Roth 
Luminol (A46859)        SIGMA 
Moviol           Hoechst 
Phusion buffer HF F-518       Finnzymes 
PMSF           SERVA Feinbiochemica 
Polyethylenimine         SERVA Feinbiochemica 
Ponceau Red          SIGMA
 
Propidiumiodide         SIGMA
 
Protein A sepharose beads 50% slurry (P3476)  SIGMA
 
Protein A/G plus agarose beads      Santa Cruz Biotech 
Protein ladder #0671        Fermentas 
TEMED (tetramethylethylenediamine)    Roth 
Tween20          Applichem 
 
 
3.2.7 Consumables 
µ-Slide 8 wells      ibidi 
Cell culture flasks     TPP 
Centrifuge tubes      TPP 
Cover slips, glass slides    Roth 
GSTrap Fast Flow     Amersham Biosciences 
Molecular sieve 0.3 nm    MERCK 
Pipette tips       Diagonal 
Reaction tubes 1,5 mL    Diagonal 
Sterile filters       Sarstedt 
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3.2.8 Devices 
Autoclave    A5      WEBECO 
Cell culture hood   Hera Safe    Heraeus instruments 
Centrifuges    MIKRO 200    Hettich 
      MIKRO 22R    Hettich 
      RC2-B     Sorvall 
      4K15C     Sigma centrifuges 
Distillation apparatus  Destamat    Heraeus instruments 
Electroph. chamber (DNA)      Mech. Workshop 
            Bielefeld Univ. 
Electroph. Sys. (Protein) 45-1010 Class II   PeqLab 
Fluorescence microscope LSM 5 Exiciter Obs. Z1 Zeiss 
FPLC     LCC 500    Pharmacia Biotech 
FPLC fraction collector RediFrac    Pharmacia Biotech 
FPLC printer   REC 102    Pharmacia Biotech 
Hood for microbiology LaminAir HB2472  Heraeus instruments 
Incubator (for bacteria)       Memmert 
Incubator (for cell culture) FunctionLine   Heraeus instruments 
Luminometer   Lumat LB 9506   Berthold 
Magnetic stirrer   IKA-COMBIMAG REO Janke & Kunkel 
Microscope    CK2     Olympus 
Neubauer count. chamber       Roth 
PCR- machine   PCR Express   HYBAID 
PCR-machine   Master Cycler Gradient Eppendorf 
pH-Meter    MP220     Mettler Toledo 
Photometer    Biophotometer   Eppendorf 
Power supply   DC Power 5004   Nishizawa 
Power supply   E0300-0.1    Delta Elektronika 
Power supply   Microcomp Electroph. Renner GMBH 
Pure water treatment plant       Millipore 
Roller     low profile roller   Stovall Lifescience inc. 
Rotor for 1.5 mL tubes C28      Labinco 
Scales     1409 MP    Sartorius 
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Scales     FA210-4iCE    Faust 
Shaker (37°C, bacteria) 3033     GFL 
Shaker     SM25     Bachofer 
Sonifier     PG.744     MSE 
Thermomixer   5436     Eppendorf 
Trans illuminator   Transilluminator 4000 Stratagene 
Ultra sonic water bath  Sonorex longlife   Bandelin electronic 
Vortex     VORTEX GENIE  BENDER&HOBEIN 
Water bath    C10      HAAKE 
 
 
3.2.9 Enzymes 
Antarctic phosphatase    NEB 
Phusion high fidelxity DNA Pol Finnzymes 
Restriction endo nucleases   NEB, Fermentas 
Taq polymerase     A. Kralemann Köhler, BioV, Bielefeld Univ. 
Trypsine (Seq. grade modified) Promega 
 
 
3.2.10 Oligo nucleotides 
The melting temperatures of all primers are calculated using the basic, the salt 
adjusted and the nearest neighbor method by the software Oligo Calc. All sequencing 
primers are optimized for an annealing temperature at 55-60°C. 
 
Primers for PCR-cloning: 
Nr. Name Target Sequence (5'-3') 
Z032 3-Primer_ 
Mitte 
p65 for SDM TCT GCC GGG AAG ATG AGG GGG 
AAC AG 
Z033 5-Primer_ 
Upstream 
pENTR/SD/D-
TOPO for SDM 
CTG GCA CGA CAG GTT TCC CGA 
CTG G 
Z034 3-Primer_ 
Downstream 
p65 in pENTR/SD 
/D-TOPO for SDM 
GAT CAG CTC CAA GGG TGG GCG 
CGC CGA 
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Nr. Name Target Sequence (5'-3') 
Z035 5-Primer_ 
Mitte 
p65 for SDM CCC CCT CAT CTT CCC GGC AGA 
GCC AGC 
Z370 p65gexfw p65 ORF Α into 
pGEX-5X-1 
TTG GAT CCC CGA CGA ACT GTT 
CCC CCT CAT CTT CC 
Z371 p65gexrv  p65 ORF Ω into 
pGEX-5X-1 
AAC TCG AGT CTA GAT TAG GAG 
CTG ATC TGA CTC AG 
Z382 pGEXIkBf IκBα ORF Α into 
pGEX-5X-1 
TTG GAT CCC CTT CCA GGC GGC 
CGA GCG C 
Z383 pGEXIkBr IκBα ORF Ω into 
pGEX-5X-1 
AAT CTA GAC TAT AAC GTC AGA 
CGC TGG CCT CCA AAC 
Z567 HSP90DW HSP90 ORF Ω into 
pcDNA3.1(+) 
AT CTA GAT TAG TCT ACT TCT 
TCC ATG CGT GAT GTG TC 
Z569 HSPA8DW HSC70 ORF Ω into 
pcDNA3.1(+) 
AAT CTA GAT TAA TCA ACC TCT 
TCA ATG GTG GGC CC 
Z608  HSP90UP HSP90 ORF Α into 
pcDNA3.1(+) 
TGG ATC CCC ATG CCT GAG GAA 
ACC CAG ACC CAA G 
Z609  HSPA8UP HSC70 ORF Α into 
pcDNA3.1(+) 
TGG ATC CCC ATG TCC AAG GGA 
CCT GCA GTT GGT ATT 
Z772 HSPA8GFP5 BamHI-HSC70 
ORF Α into 
pcDNA3.1(+)GFP 
GAG CTC GGA TCC ACC ATG TCC 
AAG GGA CCT GCA GTT GGT ATT 
Z773 HSPA8GFP3 HSC70-NotI 
ORF Ω into 
pcDNA3.1(+)GFP 
CAC CAT GCG GCC GCC ATC AAC 
CTC TTC AAT GGT GGG CCC TGA 
G 
ORF Α: open reading frame start, ORF Ω: open reading frame terminus, SDM: site 
directed mutagenesis 
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Sequencing primers 
Nr. Name Target Sequence (5'-3') 
Z015 P65_5-PrimerII p65 
part 2/3 
AAC ACT GCC GAG CTC AAG AT 
Z016 P65_5-PrimerIII p65 
part 3/3 
AGC CAT GGT ATC AGC TCT GG 
Z044 5PrimerI Pezz18 upstream 
to MCS 
GCT GCG CAA CAC GAT GAA G 
Z045 3PrimerIV P65 
part 1/3 
CTG GTC CCG TGA AAT ACA CC 
Z416 pGEX-5X-5f pGEX-5X-1 
upstream to MCS 
ATA CAT GGA CCC AAT GTG CC 
Z417 IkBaSeqII IκBα 
part 2/2 
GTG ATC CTG AGC TCC GAG AC 
Z626 HSPA8seq1fw HSPA8 
part 2/3 
TGG TCA CAG TGC CAG CTT AC 
Z627 HSPA8seq2rv HSPA8 
part 1/3 
CAG CAG CAG TTG GCT CAT TA 
Z628 HSPA8seq3fw HSPA8 
part 3/3 
TTG CTG CTC TTG GAT GTC AC 
Z629 HSP90seq1fw HSP90 
part 2/4 
CTA TGA TTG GCC AGT TCG GT 
Z630 HSP90seq2rv HSP90 
part 1/4 
CTG AGG ACT CCC AAG CGT AC 
Z631 HSP90seq3fw HSP90 
part 3/4 
GAC TGG GAA GAT CAC TTG GC 
Z632 HSP90seq4fw HSP90 
part 4/4 
AAC TCA GCC TTT GTG GAA CG 
The part describes the partition of the insert, which is covered by sequencing result 
using the indicated primer. The first part contains the start of insert's ORF. 
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3.2.11 Protease inhibitors 
Name Effective Conc. Stock conc. Supplier 
aprotinine 10 μg/mL 10 mg/mL Roth 
leupetine 10 μg/mL 5 mg/mL Roth 
NaF 10 mM NaF 500 mM in 9:1 acetic acid/methanol Roth 
pepstatine 1 μg/mL 1 mg/mL Roth 
PMSF 1 mM 100 mM in ethanol Roth 
 
 
3.2.12 Reagent kits 
DNA Extraction PC500     Macherey-Nagel 
Dual-Luciferase Assay System    Promega 
In vitro translation kit      Promega 
NucleoSpin Extract II      Macherey-Nagel 
Protein quantification kit (Rotiquant)  Roth 
 
 
3.3 Molecular biologic methods 
3.3.1 Agarose gel electrophoresis 
Depending on the size of the DNA fragments to separate the gel pore size is 
regulated by the fraction of agarose between 0.8% (w/v) – 1.5% (w/v). The amount 
of agarose is heated in an appropriate volume of TAE-Buffer to the boiling point. 
After cooling down to ca. 60°C, 0.5 g/mL ethidium bromide are added and the 
evaporated water is supplemented. The gel is casted and after polymerization, the 
DNA samples are applied with 6x DNA loading dye. A maximum of 100 ng DNA is 
loaded per millimeter gel width. The separation takes place within an electric field 
strength of 5 V/cm (Voltage / electrode distance) for ~1 h. The gel is placed on a 
transilluminator and photographed by a standard digital camera. 
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3.3.2 PCR cloning 
To insert target sequences in the desired expression vectors, all target sequences have 
to carry an appropriate restriction side and they have to carry a Kozak sequence and 
ATG (leading peptide) or must be in frame (C-terminal fusion). These features can 
be added to target sequences by PCR. Therefore, a primer is designed that carries the 
needed sequence in its overhang. For cloning purpose, a high fidelity proof reading 
polymerase from Finnzymes is used. After PCR, the product is purified by 
NucleoSpin Extract II. The DNA strand with the newly appended restriction sites can 
now be digested. The used reaction composition and PCR machine program are 
described below. 
 
PCR-Mix (50 μL): 
10 μL  5x Phusion buffer HF (high fidelity) 
1.0 μL  dNTPs 
0.5 μL  Phusion high fidelity polymerase (2 U/μL) 
3 μL  5'-Primer (10 pmol/ μL) 
3 μL  3'-Primer (10 pmol/ μL) 
31.5 μL  distilled water 
1 µL  Template (0.1 to 10 pg plasmid template) 
 
Table 3.1: Program for PCR Cloning 
Step Temperature [°C] Duration [sec] Cycle number 
Initial denaturing 94 30 - 
Denaturing 94 30 
30 Primer annealing 
variable, 
60 (standard) 
20 
Elongation 72 30 per kb 
Finale elongation 72 300 - 
Storage 10 ∞ - 
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3.3.3 Colony PCR 
The colony PCR is used to identify clones carrying the desired insert after 
transformation. Before starting the colony PCR it is controlled if the plate with the 
insert of interest shows significantly more colonies than a plate with bacteria 
transformed with the empty vector. When the ratio is adequate a number of clones is 
picked with a sterile toothpick and transferred into a 1.5 mL reaction tube with 50 µL 
water. The bacterial material is vigorously mixed with the water by scraping the 
inner walls of the tube. Afterwards the toothpick is used to inoculate 5 mL LB-
medium supplemented with an appropriate selective agent. The bacteria water mix is 
boiled for 5 min in a thermomixer. Afterwards, it is used as template for the colony 
PCR. With at least one insert specific primer, it is possible to identify the clones with 
the desired insert. 
 
PCR-Mix (50 μL): 
5 μL  10x Taq buffer (Qiagen, #201205) 
0.2 µL  MgCl 25 mM 
0.5 μL  dNTPs 
0.5 μL  Taq polymerase (1,25 U/μL) 
1 μL  5'-Primer (10 pmol/ μL) 
1 μL  3'-Primer (10 pmol/ μL) 
26.8 μL  distilled water 
15 µL  Template (boiled bacteria) 
 
Table 3.2: Program for Colony PCR 
Step Temperature [°C] Duration [sec] Cycle number 
Initial denaturing 94 30 - 
Denaturing 94 30 
30 Primer annealing 60 20 
Elongation 72 60 per kb 
Finale elongation 72 420 - 
Storage 10 ∞ - 
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3.3.4 DNA construct sequencing 
The sequencings of the DNA constructs is performed by the sequencing core facility 
of the CeBiTec at Bielefeld University. For each reaction, 3 µg DNA (250 ng/µL) 
and 10 µL 10 mM sequencing primer are sent to the institute. 
 
 
3.3.5 Dephosphorylation of cleaved vector DNA 
To prevent a religation of a cleaved vector backbone in a subsequent ligation 
reaction, the vector DNA is dephosphorylated after digestion. Therefore, an excess of 
five units of Antarctic phosphatase are added per µg DNA to the sample directly 
after restriction. It is incubated for 30 min at 37°C and Afterwards heat inactivated 
for 5 min at 65°C. 
 
 
3.3.6 Digestion of plasmid DNA by restriction endonucleases 
0.1 to 1.0 µg of plasmid DNA are incubated with one unit of the appropriate 
endonucleases for 60 min. The buffer conditions and incubation temperature is 
chosen as recommended by the supplier (Fermentas, NEB). All enzymes are heat 
inactivated by incubation for 15 min at 65°C if no higher temperature is 
recommended by the supplier. 
 
 
3.3.7 Ligation of DNA fragments 
As preparation for the ligation, both fragments, the insert and the dephosphorylated 
vector are separated by agarose gel electrophoresis. The desired bands a cut from the 
gel  with a clean scalpel and extracted with the kit Nucleospin Extract II (Macherey-
Nagel) as it is recommended by the supplier. A small fraction of the purified DNA 
samples is loaded on an agarose gel again and the DNA concentration is estimated by 
comparison with the DNA ladder bands. For the Ligation 10-40 ng vector DNA, the 
fourfold equimolar amount of the insert, two units ligase and 10x ligase buffer are 
combined in 20 µL sample volume. The ligation mixture is incubated for 2 h at room 
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temperature or at 16°C over night. The whole reaction can directly be used for 
transformation. 
 
 
3.3.8 Production of chemo competent E. coli 
200 mL LB-Medium are inoculated with a 5 mL over night culture of the desired 
bacteria strain and cultivated at 37°C and shaking with 250 rpm. The bacteria are 
cultivated till they reach an OD600 of 0.4 - 0.6. Then the culture is transferred to 50 
mL centrifuge tubes and chilled on ice for 5 min and Afterwards centrifuged for 7 
min at 1600 g. The supernatant is discarded and the pellet resuspended in 10 mL per 
tube of ice cold CaCl2 solution. The samples are centrifuged again at 1100 g for 5 
min. The supernatant is discarded and the pellet resuspended in 2 mL of ice cold 
CaCl2 solution. The suspension is aliquoted in 100 µL fractions and stored at -70°C. 
 
 
3.3.9 Transformation of chemo competent E. coli 
One aliquot of chemo competent E. coli is thawed on ice per transformation reaction 
(~10 min). Depending on whether a retransformation or a transformation of a ligation 
reaction should be performed, either 0.1-1 ng or the whole ligation reaction is used. 
This DNA is added to the bacteria in a maximum volume of 20 µL. The mixture is 
incubated for 30 min on ice. After this incubation, a heat shock at 42°C is applied. 
The duration depends on the bacteria strain and varies between 30 sec and 2 min. 
After the heat shock, the sample is cooled on ice for 2 min before 1 mL of 
prewarmed LB or 300 µL prewarmed SOC medium is added and the bacteria are 
cultivated for 1 hour at 37°C. Afterwards the bacteria are plated on LB agar 
supplemented with an appropriate selective antibiotic. 
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3.3.10 Establishing of glycerol stocks 
1 mL of fresh, saturated bacteria culture is mixed with 1 mL glycerol solution and 
frozen at minus 70°C. For use of the stock, a small ice fragment is scraped off by an 
inoculation loop. The stock may not thaw. 
 
Alternative: 
0.85 mL fresh, saturated bacteria culture are mixed with 0.15 mL Glycerin (100%) 
and frozen at -70°C. 
 
 
3.4 Protein biochemical methods 
3.4.1 Colloidale Coomassie staining 
Colloidal Coomassie staining is 20 to 100fold more sensitive than "normal" 
Coomassie staining and does not interfere with mass spectrometry measurements like 
classic silver staining. It can detect protein traces down to 5 ng. For the preparation 
of a colloidal Coomassie staining, the order of mixing the components is important. 
10% ammoniumsulfate are dissolved in half of the final water volume, then 10 % 
phosphoric acid are added. The solution is mixed and filled up to 80% of the final 
volume with water. 0.12% Coomassie brilliant blue G-250 are added and the 
solutions is stirred until no large particles are visible any longer. Directly before use, 
the mixture is filled up to 100% with methanol. 
For colloidal staining, the SDS gels need to be washed twice for ten minutes in 
distilled water to remove the SDS, which otherwise increases the background. 
Afterwards the gel is placed in the methanol containing staining solution until it 
reaches the desired intensity or for saturation over night. The contrast can be 
enlarged by washing in distilled water. 
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3.4.2 ECL 
All western blots are developed by enhanced chemo luminescence. In this technique, 
the horseradish peroxidase labeled secondary antibody catalyzes the conversion of 
the enhanced chemo luminescent substrate into a sensitized reagent in the vicinity of 
the molecule of interest. This produces on further oxidation by hydrogen peroxide, a 
triplet (excited) carbonyl which emits light when it decays to the singlet carbonyl. 
Therefore, the 50 mM Tris-Cl buffer (pH 7.35) washed blotting membranE is placed 
between two transparent plastic sheets. Per membrane (ca. 7 x 9 cm
2)
, 1 mL ECL 
solution A, 100 µL ECL solution B and 0.3 µL30% H2O2 are mixed, added to the 
membrane, covered with the plastic sheet, and dispersed to a thin layer. The chemo 
luminescence is measured immediately by a special photo camera. 
 
 
3.4.3 Purification of GST fusion proteins from E. coli 
A single colony of E. coli DH5α or BL21 DE3 pLys, transformed with the gene of 
interest in the GST expression vector pGEX-5X-1, is used for inoculation of a 5 mL 
over night culture in selective medium (LB-Medium with 100 µg/mL Ampicillin). 
This is used as starter for a 400 mL culture on the next morning. The bacteria are 
incubated at 37°C and 250 rpm until the OD600 reaches a value of 0.4 to 0.6. This 
takes between 3 and 5 hours. At this point, the culture is divided in halves and the 
protein production is induced in one culture by the addition of 1 mM isopropy-beta-
thio galactopyranoside (IPTG). The incubation is prolonged for 3 hours. Afterwards 
the bacteria are separated by centrifugation at 4500 to 6000 g for 5 min. The 
supernatant is discarded and all remaining liquid is drawn from the pellet by a 
pipette. If necessary, the pellet may be shock frozen in liquid nitrogen and stored at -
80°C. For lysis, the pellet is resuspended in 10 mL ice cold PBS and sonicated four 
times for 30 sec. The lysate is cleared by centrifugation for 15 min at 12000 g and 
4°C. The cleared lysate can directly be loaded onto the column. For the affinity 
purification, an FPLC device in combination with an 1 mL Amersham GSTrap Fast 
Flow column is used. The protein efflux is monitored by a UV spectrometer with 
printer. The flow rate is 1 mL/min. The column is equilibrated with 4 CV (4 mL) 
PBS. One to ten mL sample are applied. The column is washed until the UV 
absorption of the flow through is stable and near to the baseline, but at least with 
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10 mL PBS. The elution is performed with elution buffer (50 mM Tris, 10 mM 
glutathione, 0.1% Triton X-100 pH 8.0). This buffer is used until the UV absorption 
of the flow through is stable, but at least 5 mL. In order to clean it, the column is 
washed with 5 CV PBS, 5 CV of basic cleaning I buffer (100 mM Tris-HCl, 0.5 M 
NaCl, pH 8.5), then with 5 CV of basic cleaning II buffer (100 mM sodium acteate, 
0.5 M NaCl, pH 4.5) and 5 CV PBS. If the column is clogged with precipitated, 
denatured proteins, the solutions rigorous cleaning I (6 M guanidine hydrochloride) 
and II (70% ethanol in H20) are used. Each of them with 5 CV alternating with PBS. 
The column can be stored in 20% Ethanol in PBS for long time. 
 
 
3.4.4 Immunoprecipitation for mass spectrometry 
For each immunoprecipitation, 20 mg of brain extract protein are needed. This 
protein solution is cross linked by the addition of 0.5 mg/mL DSP (dithiobissuccini-
midylpropionate) solution in dry DMSO (final concentration 0.5 mg/mL, suitable 
stem conc. 10 mg/mL) and incubation on ice for 30 min. The cross linking is stopped 
by Tris buffer pH 8.0 at the final concentration of 25 mM which exhaust the 
remaining DSP. The cross linked protein is then mixed with 50 μL protein G 
sepharose 4B fast flow (SIGMA) and the desired amount of anti p65/RelA antibody 
(sc-8008, Santa Cruz Biot.) or antibody for the isotype control (mouse monoclonal 
IgG1, MOPC 21, SIGMA). The immunoprecipitates are spun head over tail for 2 
hours at 4°C. After the formation of the immunoprecipitates the samples are washed 
three times. Each washing step consists of a centrifugation for 1 min at 3000 g and 
the addition of 1 ml lysis buffer (brain extract protocol). After the last washing step, 
the IPs are centrifuged and the pellet is eluted in 30 µL 1 SDS sample buffer by 
heating at 60°C for 5 min. The supernatant is used for SDS gel electrophoresis and 
mass spectrometry analysis. 
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3.4.5 Immunoprecipitation for western blotting 
HEK293FT cells are transfected with Lipofectamine2000™ in a 10 cm plate scale 
for each immunoprecipitation reaction (see transfection methods). The following 
expression constructs are used: pcDNA3.1(+)c-myc-HSPA8, pcDNA3.1(+)c-myc-
HSPA8mut, pcDNA3.1(+)c-myc-HSP90, pcDNA3.1(+)Pin1, pEF-FLAGpGKpuro 
p65WT, pEF-FLAGpGKpuro p50 and pCMV c-myc-Iκε. In case of a co transfection, 
equimolar ratios of these constructs are used. The cells are harvested 36 hours after 
the transfection. For this purpose they are washed with PBS, resuspended in 1 mL of 
lysis buffer (50 mM HEPES, 150 mM NaCl, 1% NP-40 (v/v), pH 7,5) and protease 
inhibitors (1 mM PMSF; 10 μg/mL leupetine, 10 μg/mL aprotinine, 1 μg/mL 
pepstatine and 10 mM NaF). Subsequently, they are transferred to a 1mL reaction 
tube and lysed by incubation on ice for 20 min, interrupted by three 30 sec sonication 
steps. The debris are separated by centrifugation for 10 min at 14000 g and 4°C. The 
supernatant is used for the IP and the expression test. For the expression test, 50 μL 
sample are mixed with 12,5 μL 5xSDS sample buffer and loaded on a SDS-PAGE. 
For the IP, 30 μL 50% protein A sepharose beads are washed once with 1 mL PBS. 
The beads, 900 μL supernatant, and 1,5 μL (final conc. 1.0 μg/mL) rabbit ANTI-c-
Myc (C3956 SIGMA) are incubated spinning head over tail for 2 h at 4°C or 37°C. If 
indicated, 300 μL axon enriched pig brain extract (3.3 mg protein) and for 
crosslinking 50 μL DSP (in DMSO, final conc. ~0.5 mg/mL) are added for 
incubation. After this, the remaining crosslinker is exhausted by the addition of 
25 µL 1 M TrisCl pH8.0 (final conc. 25 mM) and by incubation for 15 minutes at 
4°C. The beads are centrifuged at 12000 g for 1 min and washed with 1 mL lysis 
buffer containing 50 mM Tris instead of HEPES. After five washing steps with this 
lysis buffer and one with PBS, the beads are eluted with 90 μL 1xSDS-sample buffer 
and ready to load on SDS-PAGE and western blotting. The western blotting is 
performed using the following antibodies: rabbit polyclonal Anti-Flag 1:4000 
(F7425, SIGMA), rabbit polyclonal Anti-c-Myc 1:2000 (C3956 SIGMA), and goat 
anti-rabbit IgG H+L HRP 1:4000 (111-035-144, Jackson Immuno Research 
Laboratories). 
In the experiments where the Flag tag is used for capturing, the IP is done with Anti 
Flag M2 (F1804, SIGMA) and protein A/G plus agarose beads (Santa Cruz 
Biotechnology).  
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3.4.6 Luciferase assay 
The Luciferase assay serves as a tool for the quantification of a promoter activity. It 
uses two reporter genes, which are co transfected in the cells of interest. Both genes 
encode luciferases. The firefly luciferase is controlled by the promoter of interest, the 
other one, the Renilla luciferase, by a constitutive promoter. 36 hours after the 
transfection, the expression of the luciferases correlates to the activity of their 
promoters. The two luciferase activities are measured subsequently via the 
fluorescence provoked by two different substrates. The assay is performed with 
"Dual-Luciferase® Reporter Assay System" kit from Promega in a 24well scale. 
Therefore 2x10
5
 cells are seeded per well. The cells are transfected due to the 
Turbofect® protocol (v.i.). They are transfected with 800 ng of total DNA: 200 ng of 
the NFκB Firefly Luciferase construct Enh-TK-luciferase designed by Bachelerie et 
al. [13], 100 ng of the Renilla Luciferase construct pGL4.74[hRluc/TK] Vector 
supplied by Promega and 500 ng of others (see results). The cells are harvested after 
36 hours by adding 100 µL passive lysis buffer provided by Promega and rocking for 
15 min at room temperature. This crude lysate is diluted 1:20 and stored on ice. 
Subsequently, both fluorescence values are measured according to the Promega 
protocol. The constitutive Renilla luciferase activity is used for the normalization of 
variations in the sample volume, cell viability etc. So each value is a ratio of firefly 
luciferase / Renilla luciferase. 
 
 
3.4.7 Mass spectrometry 
The MALDI TOF MS analysis was performed by Carola Eck in the CeBiTec at 
Bielefeld University (supervisor Prof. K. Niehaus) while the LC ESI MS 
measurements were done by Dr. Raimund Hoffrogge of the "Zellkulturtechnik" 
workgroup of Prof. T. Noll in the technical faculty at Bielefeld University.  
All samples are analyzed by using Mascot. This software compares the experimental 
data to in silico digested peptide spectra. In silico means that a whole human 
proteome database is virtually digested with trypsin. Therewith a unique pattern of 
fragment masses is created for each single protein. Those patterns are compared to 
the experimental ones. If many fragments of an in silico digested protein are found in 
a sample, it is more probable that the analyzed sample contains this database protein. 
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This probability is expressed by a score. The higher the score, the more improbable 
the detected ions belong to an unknown random protein. It is distinguished between 
ion scores and protein scores. Ion scores describe the significance of a single peak. A 
peak is more significant when it can be produced only from a few proteins. If a peak 
belongs to a common fragment or can be related to many fragments, it is less 
significant. So it is obvious that large masses are more significant then small ones. 
The protein scores are based on the combined ion scores. 
The MALDI TOF MS Data are compared in a peptide mass fingerprint analysis 
using a human protein data base from the Kyoto Encyclopedia of Genes and 
Genomes and no modifications are regarded. The settings for peptide mass tolerance, 
maximum missed cleavages and peptide charged state are customized for each 
spectrum. The LS ESI MS/MS data are analyzed by a MS/MS ion search referring to 
a human protein data base allowing carbamidomethy modifications and oxidations. 
Peptide mass tolerance is fixed to ±1250 ppm and fragment mass tolerance to 
±1250 mmu. Only one missed cleavage is allowed. In both cases, only monoisotopic 
mass value are regarded. 
 
 
3.4.8 Preparation gel spots for mass spectrometry analysis 
PP-Tubes (1 mL) are treated twice with 500 μL TFA 0.1% /acetonitrile 60% over 
night to extract flexibilizers. Bands are cut out of the gel with a clean scalpel and put 
into the pretreated tubes. 250 μL (100 μL for 96 well plate) acetonitrile 50%/H2O 
50% are added to the gel slice and incubated under shaking for 5 minutes at room 
temperature. The supernatant is removed and 250 μL (100 μL for 96 well plate) 
acetonitrile 50% / NH4HCO3 50 mM are added. After incubation under shaking for 
30 minutes at room temperature, the supernatant is removed again. 250 μL (100 μL 
for 96 well plate) acetonitrile 50% / NH4HCO3 10 mM are added to the gel and 
incubated for 30 minutes at room temperature. The supernatant is removed again and 
the gel slice dried over night under the flue. 20 μg trypsine (Seq. grade modified, 
Promega) are diluted in 200 μL of supplied buffer and activated for 15 minutes at 
30°C. 1 μL of trypsine solution is mixed with 14 μL NH4HCO3 10 mM and added to 
the dry gel slice. After incubation for 15 minutes at room temperature or 2 hours at 
4°C additional 20 μL (10 μL for 96 well plate) NH4HCO3 10 mM are added. The 
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mixture is incubated air tide over night at 37°C and stored at -20°C. For LC ESI 
MS/MS, potential particulate matter is segregated by centrifugation. The supernatant 
sample is transferred to a clean septum sealed tube. 
 
 
3.4.9 SDS polyacrylamide gel electrophoresis 
The analytic separation of proteins is performed by SDS polyacrylamide gel 
electrophoresis in a discontinues buffer system. The components of separating and 
stacking gel are enlisted in Table 3.3. Therefore, the separating gel is poured first 
between the glass plates sealed in a casting base of an electrophoresis system from 
Sigma Aldrich. The stacking gel is protected against evaporation by water saturated 
isopropyl alcohol during polymerization. After polymerization, the isopropyl alcohol 
is discarded and the gel is briefly washed with water before pouring of the stacking 
gel. A Teflon comb is inserted to form the sample bags. Immediately before loading, 
the sample bags are washed with running buffer and the system is checked for leaks 
by filling with running buffer and the application of voltage (one 10 x 10 cm
2
 mini 
gel has an electric resistance of ca. 4000Ω). The electrophoresis takes place at 80 V 
until the dye front leaves the stacking gel. From this time point on, the 
electrophoresis is continued at 15 mA per gel. As a molecular weight standard, the 
PageRuler prestained protein ladder #0671 from Fermentas is used (bands at 10, 17, 
26, 34, 43, 55, 72, 95, 130 and 170 kDa). 
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Table 3.3: Composition of separating and stacking gels 
 Separating gel Stacking gel 
(7.5% ) (10% ) (12% ) (3.75%) 
30% (w/v) acrylamide, 
0.8% (w/v) bis-acrylamide 
4.0 ml 5.33 ml 6.4 ml 500 µl 
Tris 3 M pH 8.8 2.0 ml 2.0 ml 2.0 ml --- 
Tris 1 M pH 6.8 --- --- --- 500 µl 
SDS 10% 160 µl 160 µl 160 µl 40 µl 
H
2
O 9.7 ml 8.4 ml 7.3 ml 1.94 ml 
TEMED 13.3 µl 13.3 µl 13.3 µl 3.5 µl 
ammoniumpersulfate 
solution 10%, fresh 
133 µl 133 µl 133 µl 35 µl 
60% sucrose --- --- --- 980 µl 
Total for two 10x10 cm 
Mini-gels 
~ 16 ml ~ 16 ml ~ 16 ml ~ 4 ml 
 
 
3.4.10 Synaptosomal extracts 
40 g of brain tissue are washed in 240 mL ice cold homogenization buffer. 
Afterwards, the tissue is homogenized in 240 mL fresh ice cold buffer in a potter (9 
strokes at 900rpm). 280 µL PMSF solution are added. The homogenized material is 
centrifuged at 850 g for 10 min. The pellet is discarded. The supernatant is 
centrifuged again at 11500 g for 15 min. The pellet is resuspended in 240 mL 
homogenization buffer and centrifuged for 15 min at 14000 g. The pellet is solvated 
in 10 mL lysis buffer. The protein concentration is measured by a Biuret Reaction 
(Rotiquant kit). For storage, 10% glycerol are added and the protein solution is shock 
frozen in liquid nitrogen and stored at -80°C. 
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3.4.11 Tissue extraction 
 
For the preparation of brain extracts, pig brain tissue is purchased in a slaughterhouse 
and transported on ice or dry ice for the frozen sample. All further steps are 
performed at 4°C. 300 g of pig brain tissue (180 g per brain) were sheared in an 
equivalent amount of lysis buffer in a blender on lowest level. One fraction of the 
hashed brain is directly used for extract, the other one is filtrated by a sieve, which 
enriches the more robust axon/myelin containing white tissue in the filter cake. The 
filter cake is mixed with the two fold amount of lysis buffer. Afterwards both, the 
whole brain and the filter cake, are sheared by ultraturax. After 30 min incubation, 
the suspension is cleared by two centrifugation steps from all insoluble contaminants: 
The first is performed at 15,000 g for 20 min. The supernatant is cleared in a second 
procedure at 40,000 g for 30 min. The protein concentration in the supernatant is 
measured by a Biuret Reaction (Rotiquant kit). The protein solution is either mixed 
with 10% Glycerol and shock frozen in liquid nitrogen or directly used for IP. 
Mouse whole brain extracts are produced analog with decreased amounts. Up to 
2 mg are used. This is equal to four mouse brains. 
 
 
3.4.12 Western blot 
Semi dry electro blot: The SDS gel is equilibrated in distilled water immediately 
after the electrophoresis for 10 min. A nitrocellulose membrane, 0.2 µm pore size, 
and six filter papers are trimmed to the same size as the gel. The nitrocellulose is 
equilibrated in distilled water, while the filter papers are incubated in the solutions 
described below. The equilibration is suitable when the nitrocellulose membrane 
show no more white blotches. The material is placed between the graphite electrodes 
of the blotting aperture in the following order: Downside (anode, positive pole), two 
filter papers (25 mM Tris, 40 mM aminohexanoic acid, 20 % methanol), one filter 
paper (30 mM Tris, 20 % methanol), nitrocellulose membrane, gel, three filter papers 
(300 mM Tris, 20 % methanol), upside (cathode, negative pole). The aperture is 
burdened with 2 kg. The transfer takes two hours at a current of 1.6 to 1.8 mM per 
cm
2
. The nitrocellulose membrane is stained reversible by 0.1% Ponceau Red 
solution. 
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Western blot: The Ponceau Red stained nitrocellulose membrane is washed in 
distilled water. Free binding sides are blocked by incubation for one hour at 37°C in 
5% skimmed milk powder dissolved in PBS. The nitrocellulose membrane is washed 
three times for 10 min with washing buffer (0.5% skimmed milk powder and 0.02% 
Tween 20 in PBS). The first antibody is applied in the appropriate buffer (see 
antibodies). 4 mL buffer volume are needed for a 9x7 cm
2
 blot. The membrane is 
applied to the inner wall of a round tube upside inside. The incubation takes place 
over night at 4°C. After the incubation, the membrane is washed again three times 
for 10 min with washing buffer (v.s.). The secondary antibody is applied in the same 
way as the first, but it is incubated only for one hour at room temperature. 
Subsequently, the blot is washed again (v.s.) and equilibrated in 50 mM Tris-Cl 
Puffer pH 7.35 for 10 min. Afterwards the western blot can be developed by ECL. 
 
 
3.5 Cell biological methods 
3.5.1 Cell culture conditions 
All cells are maintained at 37°, 5% CO2-content and 90% relative humidity. 
 
3.5.2 Cell passage 
The adherent growing cell line HEK293FT is cultivated in DMEM complete medium 
supplemented with 200 µg/mL G418 in order to maintain the plasmid 
pCMVSPORT6TAg.neo. The medium is changed at least every three days. If the 
cells are confluent, they are divided by a ratio between 1:10 and 1:20. Therefore, the 
medium is discarded and the cells are washed with a volume of PBS equal to 
medium volume. The cells are dissociated by addition of a volume of trypsin/EDTA 
solution which covers the complete surface of the cell culture dish. The trypsin is 
incubated one minute at 37°C. After trypsinization, the cells are carefully 
resuspended in an appropriate volume of medium and seeded. 
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3.5.3 Thawing and freezing of cells 
Thawing: The cells are rapidly warmed in a 37°C water bath. After the melting of the 
ice, the cell sample is mixed with 9 mL of prewarmed medium in a centrifuge tube. 
The cells are centrifuged at 210 g for 5 min. The supernatant containing DMSO is 
discarded and the cells are plated in 10 mL fresh medium. 
Freezing: After trypsinization and counting, 1-1,5·10
7
 cells are centrifuged for 5 min 
at 210 g and 4°C and resuspended in 1 mL of cold medium supplemented with 10% 
(v/v) DMSO. The cells are transferred to a cryo tube, frozen for 1-3 days at 70°C and 
stored in liquid nitrogen. 
 
 
3.5.4 Transfection methods 
Three different transfection methods are used: Transfection with Lipofectamine 
2000™ (Invitrogene) or TurboFect™ (Fermentas), with PEI (polyethylenimine) 
[147].  
Lipofectamine transfection: The vector DNA and the Lipofectamine 2000™ 
reagent amounts indicated in Table 3.4 are diluted in serum and antibiotic free 
DMEM Medium, gently mixed and incubated for 5 min at room temperature. After 
incubation, they are combined and incubated for further 20-30 min to form 
precipitates. Meanwhile, the HEK293 FT cells are seeded in a density, so that they 
are 40% confluent in antibiotic free medium. The exact number of cells can be found 
in Table 3.5. After precipitate formation, the DNA / Lipofectamine 2000™ mixture 
is added dropwise to the cells. After six hours, the antibiotic free medium must be 
replaced by Penicillin and Streptomycin containing medium. The cells can be 
harvested after 24 to maximum 48 hours incubation. 
TurboFect™ transfection: The TurboFect™ transfection is quite similar to the 
work with Lipofectamine 2000™ reagent, but there is no need to use serum and 
antibiotic free medium. Furthermore, it is not necessary to premix the reagent or 
change the medium 6 hours after transfection. 
PEI transfection: The poly cationic substance polyethylenimine works like 
TurboFect™. It forms complexes with the DNA, mask the negative charge with its 
positive amine groups, it is taken up by endocytosis, inhibits lysosomal degeneration 
of the DNA and enables their nuclear uptake. The effectiveness of PEI transfection 
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depends strongly on the molecular weight and complexity (branched, unbranched) of 
PEI. In this work, a crude mixture of PEI is used (Serva, Cat. No.: 33141.04). The 
indicated amounts of PEI and DNA (Table 3.4) are each mixed in PBS (Table 3.4), 
incubated for 5 min, combined, and incubated for 20 min at room temperature. 
Meanwhile, the number of cells for 60% confluency (Table 3.5) is seeded in a plate. 
After incubation, the DNA/PEI complexes are added dropwise. The medium is 
mixed by rocking the plate back and forth. A medium change after 6 hours is not 
necessary, but it increases the viability of the cells. The cells can be harvested after 
24 to maximum 48 hours incubation. 
 
Table 3.4: DNA and reagents amounts 
Plate 
type 
Medium / 
buffer 
Lipofectamine 2000™ TurfoFect™ PEI (1 µg/µL) 
DNA Reagent DNA Reagent DNA Reagent 
24 well 2x50 µL 0.4 µg 0.7 µL 0.8 µg 1,5 µL - - 
12 well 2x100 µL 0.7 µg 1.2  µL 2 µg 3 µL 3.2 µg 3.6 µL 
6 well 2x200  µL 1.7 µg 3.3 µL 4 µg 4 µL 9 µg 10 µL 
6 cm Ø 2x500 µL 4 µg 8 µL 6 µg 6 µL 18 µg 20 µL 
10 cm Ø 2x500 µL 10 µg 20  µL 8 µg 8 µL 54 µg 60 µL 
15 cm Ø 2x500 µL 25 µg 50  µL - - - - 
 
Table 3.5: Cell densities 
Plate type Area Cell number for 
40% confluency 
Cell number for 
60% confluency 
24 well (one well) 2.0 cm
2
 3.4x10
6
 per plate 5.1x10
6
 per plate 
12 well (one well) 3.8 cm
2
 3.0x10
6
 per plate 4.5x10
6
 per plate 
6 well (one well) 9.6 cm
2
 4.0x10
6
 per plate 6.0x10
6
 per plate 
6 cm Ø 21 cm
2
 1.3x10
6
 2.0x10
6
 
10 cm Ø 57 cm
2
 4.0x10
6
 6.0x10
6
 
15 cm Ø 150 cm
2
 1.0x10
7
 1.5x10
7
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3.5.5 Determination of cell density 
The cell number/density is determined by using a Neubauer counting chamber. 
Therefore, 10 L cell suspension are applied between the counting chamber and the 
cover slip. Four of the large, central quadrates, each containing 25 small quadrates, 
are counted and the average is calculated. The equation is valid: 
 
(1) cell density = average    x · 10
4
 cells/mL 
 
 
3.5.6 Nuclear localization assay 
A steril coverslip roughened in 80% phosphoric acid is placed in a well of a 6 well 
plate for each sample. 4x10
6
 HEK293 FT cell are seeded per six well plate and 
transfected with 4 µg of total DNA per well. The DNA mixture is composed of 1 µg 
FPred-p65 and, if indicated, 2.8 µg GFP or HSC70-GFP and/or 100 ng IκB 
expression plasmid complemented with empty expression vector. The expression of 
IκB here leads to a cytoplasmic localization of p65 by masking the NLS sequence of 
p65/RelA. For the transfection, the Turbofect® protocoll is used. After 24 hours of 
expression, the cells are washed with PBS, fixed with 4% paraformaldehyde in PBS, 
washed again twice in PBS and permeabilized by an incubation with 0.25% Triton 
X-100 in PBS for five minutes. Then the cells are washed again (v.s.) and they are 
stained with 10 µM DRAQ5 (Alexis) in PBS for 15 minutes on the coverslip. 
Afterwards, the cells are washed and embedded in Moviol with 50 mg/mL DABCO 
(1,4-Diazabicyclo[2.2.2]octan). The resin hardens over night. The flourescence is 
observed in confocal microscopy using the Zeiss Observer with a 40x planar 
Neofluar oil 1.3 objective (400 fold total magnification). The nuclear fluorescence is 
recorded via DRAQ5 (Em<max 681 nm / 697 nm intercalated to dsDNA) using a far 
red filter (551-757 nm), the fluorescence of FPredp65 is recorded using a red filter 
547-660 nm and the green fluorescence of HSC70-GFP or GFP is detected between 
492-539 nm. The fluorescence pictures are analyzed by the ZEN software. The 
nucleus, assisted by the DRAQ5 fluorescence, and the whole cell are defined as 
regions. The mean fluorescence of the red and green channel is detected and used for 
the calculation of the ratio Fnuclear/Fcell. The relative nuclear localization increases 
with this quotient. 
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3.5.7 In vivo nuclear localization assay 
HEK293 FT cells are transfected with Turbofect™ and cultivated in camber slides. 
For the transfection, a mastermix is used for cell seeding. It consists of 1.33x10
6
 cell 
combined with 3.5 µL Turbofect™ solution and 2.5 µg DNA (50% HSC70-GFP or 
GFP, 12.5% FPredp65, 5% IκBα and 32.5% pcDNA3.1) in 10 mL medium. 500 µL 
of this mastermix are seeded per well (~1 cm
2
). The cells are cultivated for 24 hours. 
Afterwards, the medium is replaced by 500 µL 37°C prewarmed Tyrode’s buffer 
[119 mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 0.5 mM MgCl2, 25 mM Glucose, 10 mM 
Hepes (pH7.33), 0.01 mM Glycine]. The cells are stimulated with 25ng/ml TNF and 
observed under a confocal microscope. The microscope is placed under a 37°C 
temperate tent. A planar apochromat 63x 1.4 Oil Objective is used. Only red and 
green fluorescence is detected. The filter settings are the same as described above.
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4 Experimental results 
4.1 Description and cloning of expression constructs 
For the subsequent described work, a number of expression plasmids is used. In the 
following, the cloning strategy used to create this constructs will be explained. The 
GST expression plasmids are created on the base of the commercial pGEX-5X-1 
vector. This plasmid promotes the expression of GST without further modifications. 
The coding sequences (CDS) for IκBα and p65 are amplified from two constructs 
supplied by Ilja Mikenberg, PhD student of Prof. Dr. C. Kaltschmidt at the 
University of Witten/Herdecke: pENTR_SD_D-TOPO_IKB-alpha-V5-His and 
SD_D-TOPO_TAP-p65(WT)-V5-His [153]. IκBα was simply amplified using the 
primers pGEXIkBf and pGEXIkBr. While pGEXIkBf contains a BamHI site, 
pGEXIkBr is designed with an XbaI restriction site. These endo nuclease recognition 
sequences are used for subsequent cleavage and ligation into pGEX-5X-1. The 
template for p65/RelA contained a point mutation. This was corrected by site-
directed mutagenesis using the primer Z032-Z035. The two hybridized products of 
site directed mutagenesis are amplified by the primers (5'-p65 in pGEX) and (3'-p65 
in pGEX). These primers enable the cloning into pGEX-5X-1 similar to IκBα. 
For the co-immunoprecipitation, the constructs pEF FLAGpGKpuro B p65 WT 
(FLAG-p65/RelA), pcDNA3.1(+)c-myc-HSPA8 (c-myc-HSPA8), pcDNA3.1(+)c-
myc-HSP90AA1 (c-myc-HSP90) and pCMV c-myc-IκBε (c-myc-IκBε) are used. 
While the last, pCMV c-myc-IκBε, was a thankful donation from the group of Prof. 
Dr. M.L. Schmitz of the institute for Biochemistry of the University Gießen, the 
other three constructs are created by PCR cloning. The original template for 
construction of the HSPA8 and HSP90 expression plasmids was ordered at 
geneservice (part of the Source BioScience plc group), see Table 4.1: Template 
origin of HSPs. The templates are amplified via the primers Z609 and Z569 (for 
HSPA8) and Z608 and Z567 (for HSP90). The PCR products with a size of 1941 and 
2259 bp are ligated into the purchasable vector pezz18 which was digested with the 
blunt end cutter SmaI. The ligation is verified by a diagnostic digestion and full 
length (CDS) sequencing (for primer sequences see Material & Methods). From this 
vector, both coding sequences are transferred to pcDNA3.1(+)c-myc using the 
BamHI and XbaI restriction sites. The vector pcDNA3.1(+)c-myc was constructed 
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by the insertion of a poly linker. It consists of two primers that encode the 
immunogen synthetic peptide corresponding to amino acid residues 410-419 of 
human c-myc protein (E Q K L I S E E D L) [21, 212]. The coding sequence is gag 
caa aag ctc att tct gaa gag gac ttg [217]. The two primers are phosphorylated, 
hybridized and ligated via KpnI and BamHI into the commercially available 
pcDNA3.1(+) (Invitrogen). The PCR cloning of HSPA8 leads to a point mutation in 
the coding base 203. Thus the triplet TTT is replaced by TGT, which leads to the 
expression of Cystein on amino acid 68 instead of Phenylalanine. The mutant is 
named HSPA8mut. The mutation is repaired by the replacement of the mutated 
sequence between the restriction sites EcoRI and PpuMI from the original clone 
HSPA8 in pCMV-Sport 6. Flag-p65/RelA was expressed using the plasmid pEF 
FLAGpGKpuro B p65 WT. This plasmid was constructed by transferring the BamHI 
/ XbaI excised p65 from pGEX-5X-1 p65 WT into pEF FLAGpGKpuro. This vector 
is offered in three variants for different reading frames, from which variant B was 
chosen for this construct. 
 
Table 4.1: Template origin of HSPs constructs 
Final construct Template Clone ID MGC Accession 
NCBI 
pcDNA3.1(+) 
c-myc-HSPA8 
HSPA8 
in pCMV-Sport 6 
3920744 17984 BC016179 
pcDNA3.1(+) 
c-myc-HSP90AA1 
pCR-BluntII TOPO 
HSP90 
40118488 149801 BC121062.2 
 
 
For fluorescence microscopy, three fluorescent fusion proteins are used: the red 
FPred-p65, HSPA8-GFP and GFP. The construct FPred-p65 was kindly supplied by 
Christin Zander, PhD student of Prof. Dr. C. Kaltschmidt at Bielefeld University. 
The GFP expression plasmid pcDNA3.1(+) GFP was constructed by Patrick 
Lüningschroer, PhD student of Prof. Dr. C. Kaltschmidt as well. 
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pcDNA3.18(+) HSPA8-GFP which was created based on pcDNA3.1(+) GFP. 
HSPA8 was amplified from HSPA8 in pCMV-Sport 6 using the primer Z772 and 
Z773 by PCR and ligated into pcDNA3.1(+) GFP via BamHI and NotI. 
All constructs are verified by diagnostic digestion or colony PCR and by sequencing 
the CDS. 
 
 
4.2 Generation of bait protein for immunoprecipitation and co IP 
For the identification of new NF-κB (RelA) interaction partners, it is necessary to 
generate a bait protein, which mimics the interaction qualities of p65/RelA and can 
be easily purified. This features makes it possible to co purify the bound interaction 
partners. The most obvious choices are a p65 fusion protein with an affinity tag or an 
anti p65 antibody, which binds the interactors via its antigen. In both cases, it is 
desirable to achieve high yields because only a little quantum will bind interaction 
partners. Therefore, only high amounts of interacting protein allow their 
identification in mass spectrometry. 
 
 
4.2.1 Expression and purification of GST fusion proteins 
In the first place, new NF-κB interactors should be isolated by a GST pull down. 
Therefore, the NF-κB subunits p65/RelA and IκB are expressed with the GST tag as 
N-terminal fusion proteins. This enables the co purification of the subunits and pre 
incubated interactors via affinity chromatography. The GST tag alone is also 
expressed to serve as negative control in the pull down experiment. To yield high 
amounts of GST fusion proteins, it is expressed in bacteria. Before its use in the pull 
down experiment, it is purified by affinity chromatography and the elution fraction is 
analyzed in mass spectrometry. 
 
The Glutathion-S-Transferase tag is encoded by the vector pGEX-5X-1 which was 
expressed in DH5α and BL21 DE3 pLys (data not shown). The expression is good in 
both strains. The major advantage of BL21 DE3 pLys over DH5α is the fact that the 
basal expression is much lower. This is important for the expression of toxic 
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proteins. A disadvantage of BL21 DE3 pLys is that it is harder to transform than 
other strains. The expression is strong no matter which bacteria strains are used and 
toxicity is no problem so that all further experiments were done with DH5α. The 
GST protein in the bacterial extracts is purified by an affinity chromatography using 
a GSTrap FastFlow column (Amersham) linked to a FPLC system (Pharmacia). The 
protein efflux can be measured by UV absorption. Figure 4.1: Affinity purification of 
GST shows the relative UV absorption during the purification of GST. From the 
collected fraction 3 to 14, a high absorption is monitored produced by the unbound 
protein. From fraction 15 to 20, the absorption decreases, while all material with no 
affinity for the glutathione matrix is washed away. Starting to collect sample 21, the 
running buffer is replaced by the elution buffer containing 10 mM Gluthatione. This 
leads to an UV elution peak between fractions 24 to 27. The delay of three fractions 
between buffer change and elution matches to the tube volume of ~3 mL. The high 
baseline of the elution buffer compared to the PBS used for loading and washing 
depends on a low content of Triton X-100 in the elution buffer. This optimizes the 
elution by inhibiting unspecific hydrophobic interactions. 
 
 
 
 
 
  
Figure 4.1: Affinity 
purification of GST 
The GST tag encoded by the 
plasmid pGEX-5X-1 was 
expressed in DH5α. The 
bacterial extract was loaded 
on a GSTrap fast flow 
column. Equilibration, loa-
ding, and washing were 
performed with GST binding 
buffer. When the UV absorp-
tion was stable, near to the 
baseline (fraction 21), GST 
was eluted by a buffer con-
taining Glutathione. 
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The coomassie stained SDS gel in Figure 4.2: Purified GST in SDS-PAGE indicates 
the protein content in the different fractions: Extract, flow through, wash and elution. 
The fractions 24, 25, 26 and 29 show a protein content of a molecular weight slightly 
bigger than 26 kDa. The band of fraction 25 is the strongest, while 24 and 26 are 
equally strong and fraction 29 shows only a faint protein trace. GST has a molecular 
weight of approximately 28 kDa so that it is quite sure that the purification was 
successful. Nevertheless, the protein from this gel band is analyzed by MS. 
 
 
 
 
 
 
 
 
 
  
Figure 4.2: Purified GST in SDS-PAGE 
The raw extract and the fraction of the affinity purification (see Figure 4.1) of GST 
was loaded on SDS gel and was coomassie stained. The lanes show the loaded 
extract, flow through and elution from left to right. The fraction number is indicated 
below the lane. The buffer change to elution buffer was done after the collection of 
fraction 21. 
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In the next two pictures, the purification of the two potential bait proteins for 
immunoprecipitation is shown. The procedure is analog to the purification of GST. 
In Figure 4.3, the fractions of the GST- IκBα purification are shown in a coomassie 
stained SDS gel. The figure shows that the glutathione affine proteins, fractions 28 
and later, could be separated from the unbound proteins, fractions 4 to 23. The 
elution fractions contain proteins of different sizes, mainly 60 kDa and 40 kDa and 
some proteins smaller than 34 kDa. The largest corresponds to the molecular weight 
of GST- IκBα which is 62.1 kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
The last of the purified proteins is GST-p65/RelA. This would be most important for 
the search of interactors. The coomassie stained SDS gel of the collected fraction is 
displayed in Figure 4.4. In the first row, the raw extract before the chromatography is 
displayed. Fraction 4 and 30 representatively show the flow through of unbound 
protein. Fraction 34 is nearly protein free, so the buffer conditions were changed for 
elution. Two fractions later, the GST affine protein is eluted. Unfortunately, there is 
Figure 4.3: Purified GST-IκBα in SDS-PAGE 
The IκBα ORF was cloned into the vector pGEX-5X-1 and expressed in DH5α. The 
bacterial extract was loaded on a GSTrap fast flow column. Equilibration, loading, 
and washing were performed with GST binding buffer. The chromatography was 
monitored by UV measurement of the efflux. The elution was started with the 
collection of fraction 25, as soon as no significant flow through was detectable in 
UV measurement. The extract and all collected fractions were loaded on SDS gel. 
The gel was stained with coomassie brilliant blue. 
 
 
Experimental results  51 
no single protein band, but a complex pattern consistent of four major sizes, namely 
~60 ~50, ~33 and ~30 kDa, and several smaller bands. Neither is there a band which 
matches the size of GST-p65 (86.6 kDa). So it is hard to tell if the visualized proteins 
are fragments of the desired GST-p65 or something else, but the result of the GST 
purification with only one band points out that the expressing bacteria do not produce 
GST affine proteins in relevant amounts. A mass spectrometry analysis should prove 
that the proteins are fragments of GST-p65. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.4: Purified GST-p65/RelA in SDS-PAGE 
The coding sequence of the p65/RelA gene was inserted into pGEX-5X-1 and 
expressed in DH5α. The bacterial extract was loaded on a GSTrap fast flow column. 
Equilibration, loading and washing were performed with GST binding buffer. The 
chromatography was monitored by UV measurement of the protein efflux. The 
elution was started with the collection of fraction 34, when no significant flow 
through was detectable in UV measurement. The extract and chosen fractions were 
loaded on SDS gel. The fractions 4 and 30 represent flow through and wash while 
34 to 40 monitor the elution. The gel was stained with coomassie brilliant blue. 
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4.2.2 MALDI-MS analysis of fusion proteins 
The mass spectrometry was performed as described in material and methods via 
tryptic digestion, but the analysis for the identification of the expressed and purified 
proteins was done in two steps. In the first one, the detected ion masses were 
correlated to theoretical mass fingerprint of the desired protein. Each correlation of 
an m/z value to a peptide mass was referred to as a match. The biotools software 
enlists the found matches and calculates the sequence and intensity coverage. In a 
second step, the spectrum was compared to an E. coli proteome data base by Mascot. 
The protein with the highest score fits best to the m/z data. This score cannot be 
related to the biotools analysis of the fusion proteins. For a direct comparison, the 
found peptide-m/z-matches and the sequence coverage must be used. If the desired 
transgenic fusion protein is not the purified one, the analyzed protein must be from 
bacterial origin. 
Figure 4.5 shows the mass spectrum of GST and the sequence covered by peptides of 
identified mass printed in red. It also gives the values for intensity (74.3) and 
sequence coverage (47.9) in percent. Additionally, the detected peptides masses are 
distributed over the whole sequence including N- and C-terminus. 
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Figure 4.5: MALDI-MS analysis of purified GST 
The putative GST band of about 28 kDa in Figure 4.2 was excised from the gel and 
analyzed in MALDI-MS. The lower window shows the protein sequence of GST. 
The fragments, which mass/charge (m/z) peaks were detected, were marked with bars 
and red letter. The dark grey and black bars refer to intense mass peaks. The upper 
window shows the mass spectrum with the peptide sequences added to the referring 
m/z peak. 
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Table 4.2: MALDI-MS results of GST samples shows data of the biotools (single 
comparison to desired protein) and mascot analysis (comparison to E. coli data base). 
The two enlisted molecular weight values are not the theoretical molecular weight of 
GST (28.0 kDa). The apparent molecular weight (first column) describes the size in 
gel (see Figure 4.2: Purified GST in SDS-PAGE) and the second molecular weight 
(MS - second column), describes the size of GST up to the last amino acid, which 
belongs to a detected/matched peptide. This values are equal because the apparent 
size corresponds to the theoretical size and the C-terminal peptide fragment could be 
detected by mass spectrometry. The third and fourth column show the sequence and 
intensity coverage resulting from the comparison of the MS data to the GST 
sequence with biotools (cf. Figure 4.5). The same comparison leads to the number of 
peptide matches to mass/charge peaks, which is represented by the number of grey 
and black bars in the lower window of Figure 4.5. The last three columns indicate the 
allocation of the MS data to the most probable E. coli protein, including the sequence 
coverage and number of matches. 
So what might be the result of this analysis? The sequence coverage to the E. coli 
exonulease IV small subunit (61%) is a little bigger than to GST (47.9%), but the 
bacterial protein is very small, only 8.9 kDa. The sequence has also only one third of 
the length of GST. This is reflected by the number of peptide to m/z matches of only 
3 in case of the E. coli exonuclease subunit to 13 matches aligning to the GST 
sequence, too. This means that it is probable that the bacterial exonuclease subunit is 
a random allocation, while the analyzed protein band really contains GST. 
 
Table 4.2: MALDI-MS results of GST samples 
Mol weight in 
kDa Seq. 
cov. 
Int. 
cov. 
Nr. 
matches 
BDB** 
Apparent MS* Protein 
Seq. 
cov. 
Nr. 
matches 
~28 28.0 47.9% 74.3% 13 
exonuclease VII 
small subunit 
61% 3 
*Sequenced to the last AA. 
**Bacterial data base search (to exclude fragments belonging to a protein of the bacterial host strain)  
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From the elution fraction 36 (cf. Figure 4.4) eight 
samples were analyzed in MS. These samples are 
indicated in Figure 4.6. The corresponding data is 
enlisted in Table 4.3: MALDI-MS results of GST-
p65/RelA (86.6 kDa) samples. Besides the 
apparent size in gel and the theoretical size of the 
protein truncated c-terminal to the last peptide 
matches in MS, the table also contains the 
calculated weight of a protein fragment, which is 
discontinued at the rare codon following on the 
last detected peptide. Although GST-p65/RelA 
has a molecular weight of 86.6 kDa, the data 
suggests that in sample one and two, GST-p65 is 
found in a truncated form. The sequence coverage 
(23.7% and 31.1%) and the number of matches 
(14 and 20) are convincingly high in relation to 
the length of the protein (778 AA). The 
comparison to the bacterial data base names two 
different proteins, the galactose operon repressor 
and the vitamin B12 dependent methionine 
synthase. The galactose operon repressor aligned 
to the first sample data is smaller (343 AA). The 
sequence coverage is in the same range (26%). 
The vitamin B12 dependent methionine synthase 
is probably not the analyzed one because it exhibits a very low sequence coverage 
9% and only ten matches although it is much longer than GST-p65 (1227 AA). 
However the most convincing argument for the identification of GST-p65 is it that in 
some of the eight analyzed samples the same peptides are found (cf. appendix 1), 
which means that these spectra contain the same m/z peaks. This is a sign for the 
presence of the same protein in the samples. Of course this GST-65 must be 
fragmented due to the apparent size in SDS gel. Evidence for the truncation can also 
be found in the MS analysis. The smaller the apparent size in gel, the fewer peptides 
are detected in MS directing from C-terminus. Furthermore, the theoretical molecular 
Figure 4.6: GST-p65/RelA 
spots analyzed by MS 
The figure shows the main 
elution fraction of the affinity 
purificated GST-p65/RelA (see 
Figure 4.4, lane 36). The 
marked bands were excised 
from the gel and analyzed by 
MALDI-MS. The result is 
enlisted in Table 4.3. 
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weight of a protein truncated directly C-terminal to the last matched peptide is 
approximately equal to the apparent size. For example, the first sample was picked 
from the gel at an apparent size of 60 kDa. In the mass spectrometric analysis of this 
sample, the last (closest to C-terminus) tryptic peptide of GST-p65, which could be 
allocated to a m/z peak, spans from AA 506 to 522 (cf. appendix 1). From N-
terminus to AA 522, GST-p65 has a theoretical molecular weight of 59.8 kDa. AA 
524 is an arginine encoded by a rare codon. The molecular weight of a GST-p65 
truncated at this codon would have a Mw of almost exact 60 kDa. These similarities 
are visible analyzing all different eight bands. 
 
Table 4.3: MALDI-MS results of GST-p65/RelA (86.6 kDa) samples 
 Mol weight in kDa 
S
eq
. 
co
v
. 
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 c
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. 
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es
 [
3
] 
BDB 
[4]
 
Nr. 
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t 
M
S
 [
1
]  
R
a
re
] 
co
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o
n
 [
2
]  
Protein 
S
co
re
 
S
eq
. 
co
v
. 
M
a
tc
h
es
 [
3
]  
1 ~60 59.8 60.0 23.7% 81.0% 14 galR 60 26% 7 
2 ~60 59.8 60.0 31.1% 74.3% 20 
Methionin 
synthase   
(metH) 
33 9% 10 
3 ~50 47.6 50.4 20.1% 89.9% 13 ygeF[5] 33 24% 4 
4 ~47 47.6 50.4 16.6% 57.7% 11 ycaJ [5] 44 20% 7 
5 ~33 34.5 35.7 13.4% 49.6% 11 
Mannose 
permease 
IIab 
38 28% 6 
6 ~32 32.5 35.7 12.0% 58.9% 10 Ycbf [5] 30 27% 4 
7 ~30 29.5 29.8 16.7% 72.5% 12 Ycbf [5] 37 35% 5 
8 ~26 25.5 29.8 11.4% 69.3% 10 Ybdm [5] 37 30% 5 
[1] Calculated mol. weight of the fragmented protein up to the last in MS detected peptide 
[2] Calculated mol. weight of the fragmented protein to the amino acid encoded by a rare triplet next 
to the last detected peptide 
[3] Matches of m/z peak (in MS) to the mass of a tryptic peptide 
[4] Bacterial data base search 
[5] Hypothetic protein 
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The elution fraction 28 (cf. Figure 4.3) 
manifests strong spots at 60 and 40 kDa and 
some weaker ones. These two and two at ca. 30 
and ca. 27 kDa are tested in MS (cf. Figure 4.7). 
The MS data was analyzed as described above. 
Sample 2 was delivered no spectrum. The 
correlation of the data to the desired GST-IκBα 
was convincing for sample 1. This sample 
showed a sequence coverage of 19.5% and 10 
matches peptides to GST-IκBα compared to a 
sequence coverage of 19.5% and 7 matches to 
the best fitting E. coli ABC transporter ATP-
binding protein. The apparent MW and the 
allocation of m/z peaks to peptides distributed 
over the whole protein sequence allow the 
conclusion that the protein has full length. 
Sample 3 and 4 exhibit only a very low 
sequence coverage, which allows no 
identification. However, four m/z peaks were 
detectable in all three samples. This peaks could 
be allocated to four peptides AA29-27, AA28-
35, AA182-191 and AA183-191. This is an 
indication for degraded GST- IκBα in sample 3 
and 4. 
  
Figure 4.7: GST-IκBα spots 
analyzed by MS 
The figure shows the main 
elution fraction of the affinity 
purificated GST- IκBα (see 
Figure 4.3) lane 28). The marked 
bands were excised from the gel 
and analyzed by MALDI-MS. 
The result is enlisted in Table 
4.4. 
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Table 4.4: MALDI-MS results of GST- IκBα (62.1 kDa) samples 
 Mol weight 
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1 
~60 
kDa 
52.9 
kDa 
19.5% 38.5% 10 
hypothetical 
ABC transporter 
ATP-binding 
protein ybit 
27 19% 7 
3 
~30 
kDa 
22.5 
kDa 
5.0% 31.6% 4 
purine nucleotide 
synthesis 
repressor 
25 12% 3 
4 
~25 
kDa 
22.5 
kDa 
5.0% 18.6% 5 
4-aminobutyrate 
aminotrans-
ferase 
33 10% 4 
[1] Calculated mol. weight of the fragmented protein up to the last in MS detected peptide 
[2] Matches of m/z peak (in MS) to the mass of a tryptic peptide 
[4] Bacterial data base search 
 
 
 
4.3 Detection of new p65/RelA interaction partners 
New neuronal NF-κB (RelA) interaction partners and potential cargo adaptors should 
be identified by immunoprecipitation of associated complexes from tissue extracts 
with an anti p65/RelA antibody. For this purpose, it was necessary produce a 
neuronal extract, which contains high levels of p65/RelA with a high affinity to the 
IP antibody and large amount of undegraded proteins.  Afterward, the proteins had to 
be separated and identified. This was done by electrophoresis and mass spectrometry. 
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4.3.1 Tissue extraction 
As a source for neuronal NF-κB interactors, the most convenient choice is 
mammalian brain tissues. The big advantage of tissues instead of neuronal cell 
cultures is that it is much easier to yield a high amount of proteins and it is certain 
that the cells are not degenerated, which often happens to cell lines. The major 
difficulty in working with tissues is that we work with non human proteins. As we 
want to investigate the human neuronal transport, the used recombinant proteins have 
the human sequence. They might not always interact with proteins of other 
mammals. For the following experiment, three tissue sources are open: mice and 
pigs. Mice or rats have the advantage that their genome is sequenced and all their 
proteins are known in sequence if not in function. Also, the phylogenetic relationship 
between rodents (rodentia) and homo is closer then between even toed ungulates 
(artiodactyla) and homo. The pig's genome is not fully sequenced yet. This makes it 
harder to identify protein in mass spectrometry, because the similar, but slightly 
different human genome must be used after mass spectrometry for the peak 
allocation. 
Before using neuronal protein extracts for immunoprecipitation, different extraction 
protocols were tested. The protein yield was determined by a biuret test. All samples 
were checked for degradation by electrophoresis and consecutive coomassie staining. 
Additionally, the extracts were tested for NF-κB (RelA) with sc-8008. By performing 
a final ultracentrifugation step, it was ensured that the extracts only contain soluble 
proteins. 
The following coomassie stained gel shows a distinct band pattern. This excludes a 
high level of degradation. In this connection, the mouse tissue extracts are most 
distinct, followed by the pig's synaptosomal extract, axonal enriched extracts and at 
least the pig's whole brain extracts. Additionally, the differences in the pattern show 
the diversity of sample origin. The signal in western blot is the strongest if axon 
enriched pig brain is used. RelA is easily detectable in the pig whole brain extracts, 
too. The signal of pig synaptosomal and mouse brain extracts is poor. The protein 
concentration indicated in Table 4.5 shows that the high amount of starting material 
in case of the pig in contrast to the mouse tissues leads to 10 to 20 fold higher final 
concentrations. The final volume of protein solution of mouse brain extracts are 
about 10 mL. This volume is also 20 fold larger if using pig material. 
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Table 4.5: Protein concentration determined by Biuret test 
Extraction Whole 
brain 
mouse 
Synaptosome 
pig 
Axon 
enriched 
pig 
Whole 
brain pig 
frozen 
Whole 
brain pig 
Concentration 0.8 mg/mL 14 mg/L 11 mg/mL 20 mg/mL 9 mg/mL 
 
 
4.3.2 MALDI-MS analysis of immunoprecipitates 
The experiment for the identification of novel NF-κB interactors is described in 
Figure 4.9. The porcine brain extracts were used as a source of neuronal proteins 
from which NF-κB interactors were precipitated and identified. Therefore, the 
extracts were incubated with an anti p65/RelA antibody (sc-8008) and protein G 
sepharose beads in presence of the cross linker DSP (dithiobis[succinimidyl-
propionate]) (Figure 4.9, step 1). The immunoprecipitates of anti p65/RelA and an 
Figure 4.8: Protein extracts in coomassie staining and anti RelA blot 
The neuronal extracts were prepared as described and 20 µg of each 
protein sample were loaded on SDS gels. Two gels were run parallel, one 
was coomassie stained, the other one was used for a western blot with anti 
p65/RelA (sc-8008). 
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unspecific antibody of the same subclass (MOPC21) for isotype control were 
separated by a one dimensional SDS-PAGE (step 2). Both lanes of the SDS-gel were 
cut into 36 slices (step 3). All samples were tryspin digested and analyzed in 
MALDI-MS. Seven slices were additionally tested in LC-ESI-MS/MS (step 4). 
Those seven slices were highlighted in red (step 3). The mass spectrometry data was 
analyzed by Mascot (step 5). Only proteins which were absent in the isotyp control 
were referred to as a hit (6). 
 
Figure 4.9: Flow chart - identification of p65/RelA interactors 
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The mascot analysis is a fingerprint analysis using a human protein data base from 
the Kyoto Encyclopedia of Genes and Genomes (KEGG). No modifications were 
regarded. The settings for peptide mass tolerance, maximum missed cleavages and 
peptide charged state were customized for each spectrum. All proteins with a score 
bigger than 56 are significant p<0.05. Additionally, the identified ones had to be of 
the same size or smaller than the excised band in the SDS-PAGE indicates, because 
oligomeres were disrupted by the reducing and denaturing properties of the SDS 
loading buffer. A protein with significant smaller molecular weight than the protein 
fraction in the gel slices could not be the detected one. The identified peptide might 
have a larger molecular weight than the gel indicates. This occurred when the 
analyzed protein was a degraded fragment, but in this study this was not the case. 
Either the degradation of the extracts was on a very low level or the score of those 
degraded proteins was too low. The score of identifying a degraded protein fragment 
is always smaller compared to a full length protein because the number of mass 
peaks is restricted. An ion derived from the missing part cannot be found. 
 
The following proteins were identified in order of their molecular weight: clathrin, 
heavy polypeptide (Hc), MW: 191493, score: 144; dynamin 1, MW: 97346, 
score: 71, heat shock 70kDa protein 8 (HSC70), MW: 70854, score: 101; NEFL; 
neurofilament, light polypeptide MW: 61739, score 73; tubulin alpha 6 MW: 49863, 
score 79 (multiple hits); beta 5-tubulin, MW: 49639, score 108; beta actin, 
MW: 41710, score: 76 (multiple hits); hepatoma-derived growth factor, related 
protein 3, MW: 22606, score 59 (multiple hits). The given molecular weight is the 
nominal mass of the unmodified peptide chain. Multiple hits means the protein could 
be found in more than one sample. These proteins are enlisted in Figure 4.10 next to 
the gel slice where they are detected. 
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Figure 4.10: Protein hits in MALDI-MS 
Porcine brain extract were immunoprecipitated with anti p65/RelA AB on 
protein G sepharose and complexes stabilized by cross linking with DSP. An IP 
with the AB MOPC21 served as isotyp control. The IP were separated in a 1D 
SDS gel. Each lane (p65/RelA precipitate and control) were cut into 36 slices 
and prepared for MS by trypsin digestion. All 36 slices were analyzed by 
MALDI-MS. The data was analyzed by Mascot comparing to a KEGG human 
protein data base. Only proteins with a score >56 (p<0.05) were regarded. Only 
if a protein was absent in the corresponding isotyp control, it was considered as a 
specific hit. All hits were marked next to the corresponding gel segment. 
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4.3.3 LC-ESI-MS/MS Analysis of immunoprecipitates 
The liquid chromatography electro spray ionization tandem mass spectrometry has 
two major advantages over matrix assisted laser desorption ionization mass 
spectrometry. The first one is that the liquid chromatography allows an additional, 
very restrictive size separation of samples before mass spectrometry analysis. That is 
quite important because although a gel separation has been performed, there is still a 
batch of proteins in every slice. The more complex the sample mixture is, the more 
complex is the spectrum. A complex spectrum makes it difficult to identify proteins 
because the scores are lower. The second advantage of LC-ESI-MS/MS is that two 
measurements can be performed. One is carried out after mild ionization of the 
particles embedded in small droplets of solvent with nearly no fragmentation and a 
second with fragmented particles. This enables the measurement of masses of the 
whole tryptic fragments and provides information about characteristic fragmentation. 
This leads to much higher score values. Seven samples, which contain a mixture of 
proteins according to the MALDI-MS analysis, are chosen to be tested in LC-ESI-
MS/MS (Figure 4.11). These samples in a range of about 95 to 60 kDa and 27 to 24 
kDa should also contain the p65/RelA subunit and in the last case, the IgG light 
chain of the IP antibody. 
The LS ESI MS/MS data were analyzed by a MS/MS ion search referring to a human 
protein data base allowing carbamidomethyl modifications and oxidations. Peptide 
mass tolerance was fixed to ±1250 ppm and fragment mass tolerance to ±1250 mmu. 
Only one missed cleavage was allowed. In both cases, only monoisotopic mass value 
were regarded. The better accuracy of the LC-ESI-MS/MS data allows to set a higher 
threshold of a sore of 80. 
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The following protein hits from MALDI-MS could be confirmed by LC-ESI-
MS/MS: Dynamin 1, MW: 89521 score: 225; HSPA8, MW: 70854, score 416 
(multiple hits); putative uncharacterized neurofilament, light polypeptide, 
MW: 61392 score: 279 (multiple hits); Tubulin alpha-6, MW: 49791 score: 109. The 
following new hits were detected: HSP90 alpha (cytosolic), class A member 1, 
MW: 84607, score: 701; HSP90 alpha (Cytosolic), class B member 1,  MW: 83212, 
score. 521; highly similar to Dihydropyrimidinase-related protein 2, MW: 58126, 
score 315 (multiple hits); Immunoblobulin light chain (Fragment), MW: 24015, 
score: 80. Only the three heat shock proteins HSPA8 (HSC70), HSP90AA1 and 
HSP90AB1 can be related to a unique sequence with the indicated molecular size. In 
all other cases there a number of transcription variants or related proteins, which 
could be also the detected one.  
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Figure 4.11: Additional protein hits in LC-ESI-MS/MS 
Porcine brain extract were immunoprecipitated with anti p65/RelA AB on protein G 
sepharose and complexes stabilized by cross linking with DSP. An IP with the AB 
MOPC21 served as isotyp control. The IP were separated in a 1D SDS gel. Each lane 
(p65/RelA precipitate and control) were cut into 36 slices and prepared for MS by 
trypsin digestion. All 36 slices were analyzed by MS. Seven samples in range of 95 
to 60 and 27 to 24 kDa were additionally analyzed by LC-ESI-MS/MS. This data 
was analyzed by Mascot comparing to the human protein data base from UniProt. 
Only proteins with a score >80 were regarded, if those proteins were absent in the 
corresponding isotyp control. The figure shoes the protein hits next to the 
corresponding gel segment. The new by LC-ESI-MS/MS detected proteins were 
marked red and confirmed hits of the former MALDI-MS were labeled by an 
exclamation mark. The MALDI-MS hits were signed in black letters.  
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Figure 4.12: IP proof of 
principle (scheme) 
4.4 Verification of NF-κB / HSP interactions by co-immunoprecipitation 
Co-immunoprecipitation is used to detect protein-protein interactions. Therefore the 
first hypothetical interaction partner is coupled via an antibody to a matrix or bead 
which can be separated by centrifugation/sedimentation. If the second interaction 
partner is present, it is separated, too. The second protein can be detected for 
example by western blot afterwards. The co-immunoprecipitation is chosen for 
verification of the hypothetical interactions, because it is very reliable method in one 
direction. That means that on the one hand, it easily produces false negative results, 
but hardly false positive. There are many reasons for false negative results: low 
signal intensity, not physiological conditions or in the worst case the antibody 
epitope is blocked by the interaction. False positive results can virtually only appear 
by unspecific binding, for example between the second interactor and a capturing 
antibody. This can be excluded by additional controls. That means an interaction 
detected by Co-IP is surely possible in vivo, but it is also possible that two proteins 
which interact in vitro do not meet in vivo, so that although they can interact they 
will not interact. Hence it is necessary to verify if there is a biological function of this 
interaction. 
 
 
4.4.1 Setting of immunoprecipitation conditions 
The function of an immunoprecipitation assay is strongly 
affected by some surrounding conditions. First, the 
presumed interaction partners must be present in 
sufficient and stable concentration. That means for the 
following experiments, that a high and stable expression 
rate is needed. Second, the antibodies need to bind their 
target specifically and sensitively under the chosen 
general conditions. At last, the buffer conditions must 
support the extraction of the proteins and keep them 
dissolved, but also enable the interaction. For the first 
purpose, detergents are added to the immunoprecipitation 
buffer which may inhibit the interaction, particularly if 
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they are too strong or too highly concentrated. A preceding attempt with common 
RIPA (radio immunoprecipitation assay) buffer recipes containing sodium 
deoxycholate showed no interaction (data not shown). All experiments were 
performed in the presence of the mild detergent NP40 and small amounts of Triton 
X-100 (used for the brain extracts). 
The following western blotted immunoprecipitates should demonstrate that the 
chosen conditions were appropriate to detect protein-protein interactions. The Flag 
tagged NF-κB subunit p65/RelA should co precipitate with its well known interactor 
IκBα, which is endogenously expressed by the cell line HEK293 FT. The western 
blot shows the expression controls in the left column. The upper Flag band indicates 
that the transgenic Flagp65 is expressed. The lower excerpt shows a part of a IκBα 
band on the right, indicating that also endogenous IκBα is present. The middle 
column shows the isotype controls produced by performing the IP with an unspecific 
antibody of the same isotype as the capturing antibody Flag M2. The isotype control 
is empty, so neither IκBα nor any unknown cross reacting protein binds to mouse 
IgG1 or the beads. The right column shows a strong Flagp65 and a weak, but clear 
IκBα signal after immunoprecipitation with anti Flag M2 mouse IgG1. This indicates 
that Flagp65 is precipitated and IκBα is co purified. 
 
 
 
 
 
 
 
Figure 4.13: IP proof of principle 
Three 6 cm plates of HEK293 FT 
cells were transfected with FLAGp65 
according to the Lipofectamin 
2000™ protocol. The cell harvest 
took place after 39 h. The lysate was 
used for two IPs with anti Flag M2 
antibody and isotype control. The 
precipitate and the crude lysate were 
checked for Flag epitope (upper 
panel) and endogenous IκBα (lower 
panel). 
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4.4.2 Immunoprecipitation of p65 / HSP complexes without crosslinker 
After the establishment of the method, the buffer conditions and protein input were 
applied to the Co-IP of the proteins of interest p65/RelA, HSC70, and HSP90, which, 
as heat shock proteins, seem to be quite probable candidates for NF-κB transport. 
The antibody setting is changed. To avoid the use of lots of different antibodies, 
which all had to be tested in a western blot, both interaction partners were tagged. 
The anti myc antibody has proven to be very sensitive and specific. It was used as the 
capturing antibody for IP. That means the myc-tagged interaction partners were next 
to the beads and Flagp65 was the second interactor to detect. The first used Flag M2 
antibody was replaced by a polyclonal rabbit anti Flag antibody (F7425) in the 
western blot, which is less specific (irrelevant band below 40 kDa), but more 
sensitive. As a positive control for an NF-κB interaction, the IκBε subunit was used. 
The isotype control was replaced by samples transfected with only one interaction 
partner. This avoids false positive results by hypothetical proteins which might 
specifically cross react with both antibodies (myc-Flag) or capturing antibody and 
second interaction partner. 
Because HEK293 is a kidney cell line and does probably not express all proteins 
which are needed for axonal transport on a sufficient level, we added axon enriched 
brain extracts to mimic axonal conditions. In case that HSC70, HSP90 and p65/RelA 
are part of a multi protein complex in axonal transport, the extract should provide 
potential missing complex subunits. The used HSC70 construct carried a mutation in 
the ATPase domain (Phe68→Cys) as a consequence of a point mutation during the 
cloning procedure. The effect of this mutation was unknown and will be compared to 
the wild type later. 
The next figure shows top down the detected Flag tagged p65/Rela after IP, the myc 
tagged first precipitated protein, the Flag tagged protein in untreated lysates and the 
myc tagged proteins in untreated lysates. 
The lowest western blot excerpt in Figure 4.14 shows the expression controls of the 
myc tagged proteins. The spots in column 2 and 5 indicate the expression of HSC70, 
3 and 6 the expression of HSP90 and 3 and 7 the expression of IκBε. Their different 
heights reflect their molecular masses of ~53 kDa (IκBε), 70 kDa (HSC70) and 90 
kDa (HSP90). The next excerpt above shows the expression of Flag tagged p65/RelA 
in the lysates. A spot indicates Flag-p65 in column 1, 5, 6, and 7. The second part of 
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the figure top to bottom shows the IP controls: The myc tagged proteins directly 
captured by the anti myc antibody used for IP. In all samples where a myc tagged 
protein is expressed, it is precipitated by IP (column 2-7). In this western blot, the 
Immunglobuline heavy chain (IgG Hc, ~50 kDa) of the capturing antibody is also 
detectable. The upper excerpt shows that under the chosen conditions an interaction 
of p65/RelA neither to HSC70 nor to HSP90 was detectable (column 5 and 6). 
Precipitation of IκBε leads to co-precipitation of Flag65/RelA (column 7). That 
means the experimental configuration is in principle suitable for the detection of an 
interaction, but the result "there is no interaction" could also be false negative due to 
a weak interaction and low signal intensity (v.s.) or using a mutated HSC70.  
 
 
 
 
 
 
 
  
Figure 4.14: p65/RelA and HSP CoIP without crosslinker 
For each sample, one 10 cm plate was transfected with the indicated constructs 
according to the Lipofectamin 2000™ protocol. Cells were harvested after 36 h and 
lysate supernatant used for IP. Capturing antibody was rabbit anti myc on protein A 
sepharose beads. The IP was performed in presence of axon enriched brain extracts. 
The four panels show top down the anti Flag blot after IP, the anti myc blot after IP, 
the anti Flag blot of the HEK-lysates and anti myc blot of HEK-lysates. p65/RelA 
combined with IκBε served as positive control. 
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Figure 4.15: Chemical structure of 
DSP 
4.4.3 Cross linked immunoprecipitation of p65 and heat shock protein 
complexes 
To increase the sensitivity of the co-
immunoprecipitation, the experiment was 
repeated in presence of a cross linking 
reagent: DSP (dithiobis[succinimidylpropio-
nate]). DSP is a homobifunctional N-
hydroxysuccinimide ester (NHS-ester) of a 
molecular weight of 404.42 kDa. This cross linker is thiol-cleavable and forms 
peptide bonds with primary amines with N-Hydroxysuccinimide (NHS) as leaving 
group. The spacer arm length is 12 Å. It can cross link any two primary amines (of 
Lysine or Arginine) with a fixed distance of up to 12 Å. That does not mean that a 
direct interaction is necessary, but there must be at least a physical association with 
mediators. The HSC70 Phe68→Cys mutant was still in use. 
 
With the complexes crosslinked by DSP, an interaction between p65/RelA and 
HSC70 was detectable (see Figure 4.16, column 5, IP αFlag). In all other matters, the 
result was similar to the previous ones without cross linking. 
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Figure 4.16: p65/RelA and HSP CoIP cross linked 
For each sample, one 10 cm plate was transfected with the indicated constructs 
according to the Lipofectamin 2000™ protocol. Cells were harvested after 36 h and 
lysate supernatant was used for IP. Capturing antibody was rabbit anti myc on 
protein A sepharose beads. The IP was performed in presence of axon enriched 
brain extracts and complexes were cross linked with DSP. The four panels show 
top down the anti Flag blot after IP, the anti myc blot after IP, the anti Flag blot of 
the HEK-lysates and anti myc blot of HEK-lysates. p65/RelA combined with IκBε 
serves as positive control. 
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4.4.4 Decrease of p65/RelA-interaction by HSC70 mutant 
During the cloning of the HSPA8 construct, the random mutant Phe68→Cys was 
produced. This mutation is located in the ATPase domain [216]. The interaction 
characteristics of this mutant were compared to the wild type. 
The differences are displayed in Figure 4.17. Column 1 and 2 (wild type and mutant) 
show the negative controls with either Flagp65 or HSC70. Column 3 displays the 
positive control, the interaction of p65/RelA and IκBε. The fourth column shows the 
pattern of interest: the p65/RelA and HSC70 association. While the wild type shows 
an interaction band in the Flag blot, there is none using the mutant at the same degree 
of intensification. 
 
 
 
 
 
 
 
 
 
Figure 4.17: Decrease of p65/RelA interaction by HSC70 Phe68→Cys 
mutant 
A 10 cm plate per sample was transfected with the indicated constructs according 
to the Lipofectamin 2000™ protocol. Cells were harvested after 36 h and lysate 
supernatant was used for IP. Capturing antibody was rabbit anti myc on protein A 
sepharose beads. The IP took place in presence of 0.5 mg cross linker and 3.3 mg 
brain extract per reaction. The panels show top down the anti Flag blot after IP, 
the anti myc blot after IP and anti Flag blot and anti myc blot of the lysates. 
p65/RelA combined with IκBε serve as positive control. 
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4.4.5 Dependence of p65 / HSC70 interaction on neuronal proteins and/or 
ATP 
The next question to answer is, is the interaction of RelA/p65 and HSC70 specific for 
neurons. A specificity for neurons can be based on the requirement of certain 
mediators with form a stable multi protein complex together with RelA/p65 and 
HSC70. These mediators could only be expressed in some cells, e.g. in neurons. In 
previous tests, there was always added protein extract from porcine brain tissue. This 
should enable the formation of neuron specific multi protein complexes. The next 
tests served to check if the addition of the protein extract is necessary or if the 
interaction takes also place in an unmodified HEK293 cell lysates. Secondly, it was 
tested if an increased level of ATP influences the interaction. HSC70 exhibits an 
ATPases activity and can undergo conformational changes like other heat shock 
protein and multimerize in dependence to the ATP level, which all effects the 
function of HSC70. In this experiment, the HSC70 wild type was used. 
Figure 4.18 shows an interaction p65/RelA with HSC70 only if a cross linker is 
added (column 5). In this sample, no neuronal protein extract is present. For this 
reason, the brain extract and the presence of neuronal proteins is not essential for the 
interaction. The addition of ATP alone does not enable the detection of the uncross 
linked interaction complex (column 6). The interaction in column 5 seems to be 
stronger than in former experiments. This could be based on the mutant wild type 
exchange and must be compared directly. 
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To find out if the addition of neuronal proteins from axon enriched brain extracts 
stabilizes the interaction complex, this had to be tested based on the cross linked 
system. In Figure 4.19, the association of p65/RelA and HSC70 is monitored in 
presence of cross linking reagent and neuronal proteins in relation to only cross 
linked, to only neuronal protein supplemented and to untreated sample. The first of 
Figure 4.18: Depends p65/RelA - HSC70 interaction on ATP and neuronal 
proteins? (pretest) 
For each sample, one 10 cm plate was transfected with the indicated constructs 
according to the Lipofectamin 2000™ protocol. Cells were harvested after 36 h and 
lysate supernatant was used for IP. Capturing antibody was rabbit anti myc AB on 
protein A sepharose beads. The IP took place in presence of 0.5 mg cross linker, 
3.3 mg brain extract and 1 µmol ATP per reaction if indicated in a column. The four 
panels show top down the anti Flag blot after IP, the anti myc blot after IP, the anti 
Flag blot of the HEK-lysates and anti myc blot of HEK-lysates. p65/RelA 
combined with IκBε serves as positive control. 
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these settings shows a definite sign of interaction (Figure 4.19 column 5). The second 
cross linked sample without neuronal proteins illustrates a faint band (column 6), 
while both samples without cross linker show none (column7 and 8). The proteins 
from porcine brain extracts seem to be non essential, but beneficial for the 
association. 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Neuronal proteins influence p65/RelA and HSC70 interaction 
For each sample, one 10 cm plate was transfected with the indicated constructs 
according to the Lipofectamin 2000™ protocol. Cells were harvested after 36 h and 
lysate supernatant was used for IP. Capturing antibody was rabbit anti myc on 
protein A sepharose beads. The IP took place in presence of 0.5 mg cross linker and 
3.3 mg brain extract per reaction if indicated in a column. The two panels show top 
down the anti Flag blot after IP and the anti myc blot after IP. p65/RelA combined 
with IκBε serves as positive control. 
 Figure 4.20: 
Lysate/Expression controls 
appendant to Figure 4.19. 
The upper panel shows the 
anti Flag blot of the HEK-
lysates and the lower one the 
anti myc blot of HEK-lysates 
related to the IPs in Figure 
4.19. 
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4.4.6 ATP and temperature dependence of p65/RelA & HSC70 complex 
formation 
To analyze the relevance of ATPases activity of the HSC70 subunit for the 
interaction, it was observed under increasing ATP concentrations. Parallel the 
influence of temperature on the interaction was checked, because temperature could 
be needful for catalytic activity of HSC70 or the kinetic of complex formation. 
The upper panel in Figure 4.21 shows the interaction band: The signal of the flag 
tagged second interactor p65/RelA. All cross linked samples interact. If the IP is 
performed at 37°C, the cross link is dispensable. ATP does not enable p65/RealA 
and HSC70 to associate in absence of a crosslinker. There is only a weak correlation 
between ATP concentration and the signal intensity of co IP. Only the sample 
incubated with 1 mM additional ATP shows a slightly stronger signal. The 0 µM and 
1 mM sample show double bands, while there are single bands at 10 and 100 µM 
ATP. All controls show the expected signals: the immunoprecipitated first interactor 
myc-HSC70 (second panel from top) and the expression controls prepared from the 
lysates (the two smaller panels). 
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Figure 4.21: ATP and temperature dependence of p65/RelA & HSC70 complex 
formation 
A 10 cm plate per sample was transfected with Flagp65/RelA and myc-HSC70 
according to the Lipofectamin 2000™ protocol. Cells were harvested after 36 h and 
lysate supernatant used for IP. Capturing antibody was rabbit anti myc on protein A 
sepharose beads. The upper two panels show the western blots after IP, the two lower 
panels present the WBs of the expression controls/lysates. The samples were 
incubated for the IP in presence of the indicated ATP concentration and 4°C or 
without ATP at 37°C. All experiments were performed with and without cross 
linking reagent (0.5 mg) and with 3.3 mg brain extract per reaction. 
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4.5 Functional test for HSC70 influence on NF-κB activity by luciferase assay 
The functional relevance of HSC70 on NF-κB activity was tested with the Dual-
Luciferase® Reporter Assay of Promega. The used cell line was HEK293 FT. The 
fluorescence measurement took place 36 hours after transfection with the luciferase 
reporter genes and the indicated expression constructs. The measured relative 
fluorescence reflects the NF-κB activity. It was calculated by normalization of the 
NF-κB dependent firefly luciferase fluorescence value with the constitutive Renilla 
luciferase fluorescence value. 
The assay was tested by overexpression of p65/RelA. Overexpression of p65/RelA 
with 500 ng of construct enhances the NF-κB activity 63-fold (column 1 & 3, Figure 
4.22, P<0.01 Newman-Keul's test), while a fifth of this amount still increases the 
activity 32-fold (column 1 & 4, Figure 4.22). This is significantly lower, reduced to 
about half of the activity of the sample group with 100% (500 ng) p65/RelA 
construct (column 3 & 4, Figure 4.22, P<0.05 Newman-Keul's test). The 
overexpression of HSC70 alone does not show an effect (column 1 and 2, Figure 
4.22). 
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Figure 4.22: Luciferase 
assay - proof of 
principle 
2x10
5
 HEK293 FT cells 
per sample were trans-
fected with the luciferase 
reporter constructs and 
additionally with 500 ng 
vector DNA composed 
of HSC70 or p65/RelA 
and complemented with 
empty expression vector. 
The NF-κB activity was 
measured via a luciferase 
reporter gene assay 
(n=5). 
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To test the assumption that there is a positive correlation, maybe a proportional 
relationship at an appropriate expression range, between HSC70 expression and NF-
κB activity, the last was measured at increasing HSC70 levels. This was done in 
presence of slight overexpression of p65/RelA (100 ng of expression vector) to have 
an intensified NF-κB activity and increased overall effects. Although the individual 
errors of each value lead to insignificant differences between the samples with 
increasing HSC70 expression, the overall slope is significantly larger than zero 
(Figure 4.23). The correlation coefficient of a linear regression is 0.9215. Based on 
the slope of the regression line, the NF-κB activity increases by 47 to 156% while the 
amount of HSC70 expression vector is raised from zero to 400 ng. 
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Figure 4.23: HSC70 increases NF-κB activity 
2x10
5
 HEK293 FT cells per sample were transfected with the 
luciferase reporter constructs and additionally with 100 ng of 
p65/RelA construct and increasing amounts of HSC70 construct 
complemented with empty expression vector. The NF-κB activity 
was measured via a luciferase reporter gene assay (n=5). 
Experimental results  81 
In the next presented luciferase assay, larger groups of samples are compared. The 
first samples were transfected with 50 ng of p65/RelA construct complemented to 
500 ng with an empty expression vector. The second sample group was transfected 
with 50 ng of p65/RelA and 450  ng of HSC70 construct. The last group was 
transfected like the first, but treated with deoxyspergualin 24 hours before lysis and 
luciferase measurement. 
The HSC70 transfected cells show a significant increase of ca. 32% in NF-κB 
activity compared to the first control group (column 1 & 2 in Figure 4.24, P<0.001, 
Tukey's Test). The DSG treatment results in no alteration in NF-κB activity. 
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Figure 4.24: HSC70 increases NF-κB activity 
2x10
5
 HEK293 FT per sample were transfected with the luciferase reporter 
constructs and with 50 ng of p65/RelA construct. Additionally the first and the last 
sample group were transfected with 450 ng empty expression vector while the 
second was transfected with 450 ng of HSC70 expression vector. The third sample 
group was incubated for 24 h in presence of 10 µg/mL deoxyspergualin (DSG). The 
NF-κB activity was measured via a luciferase reporter gene assay (n=16). 
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4.6 Nuclear localization assay 
The following experiment serves to test if an increased HSC70 expression level 
effects the nuclear localization of the NF-κB subunit p65/RelA. Therefore HEK293 
FT cells were transfected with an FPred-RelA expression construct and partially with 
a HSC70-GFP or a GFP expression vector. Because the used cell line has a high 
endogenous expression and a high state of nuclear p65/RelA, an NF-κB inactive state 
was achieved by co expression of the NF-κB inhibitor IκB. For the assay, the 
transfected cells were fixed, nuclear stained with DRAQ5, embedded and 
photographed under a confocal microscope. Only double transfected cells, controlled 
by the red fluorescence of FPred-p65 and the green fluorescence of either GFP or 
HSC70-GFP were used for analysis. The nucleus and the whole cell body were 
defined as regions and their mean fluorescence is detected. The localization of the 
fluorescent proteins was measured as a ratio of mean fluorescence in nucleus divided 
by mean fluorescence in the whole cell. Therefore, a high ratio means a strong 
nuclear localization while a smaller ratio means that most of the fluorescence was 
cytoplasmic. 
 
 
The next diagram shows that the co expression of IκB leads to a significant decrease 
of nuclear p65/RelA as it was expected, no matter if the cells are co transfected with 
GFP (column 1 & 3, Figure 4.25, p<0.001, Newman Keul's test) or HCS70-GFP 
(column 2 & 4 Figure 4.25, p<0.001, Newman Keul's test). The new result is that 
HSC70 increases the nuclear localization of RelA/p65 in comparison to GFP in the 
active state without additional IκB (column 1 & 2 Figure 4.25, p<0.05, Newman 
Keul's test). In presence of IκB, HSC70 leads to no significant difference in 
p65/RelA localization (column 3 & 2 Figure 4.25). 
Experimental results  83 
Relative p65/RelA fluorescence
- /
 G
FP
- /
 H
S
C
70
B
 / 
G
FP
I B
 / 
H
S
C
70
I
0.8
1.0
1.2
1.4
- / GFP
IB / GFP
- / HSC70
IB / HSC70
*
***
***
n.s.F
n
u
c
le
a
r/
F
c
e
ll
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.25: Relative p65/RelA fluorescence 
4x10
6
 HEK293 FT cell were seeded in a six well plate and transfected with 4 µg 
of total DNA per well. The DNA mixture was composed of 1 µg FPred-p65 and, 
if indicated, of 2.8 µg GFP or HSC70-GFP and/or 100 ng IκB expression plasmid 
complemented with empty expression vector. After 24 h of expression the cells 
were fixed, embedded and observed in confocal microscopy. The mean 
fluorescence of FPred in the nucleus and the whole cell was recorded and the ratio 
calculated. Sample sizes were: -/GFP n=36, -/HSC n=46, IκB/GFP n=53, 
IκB/HSC70 n=37. 
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If HSC70 is important for p65/RelA nuclear transport, it must respond itself to the 
trigger we used for NF-κB nuclear localization. Parallel to the nuclear / cell ratios of 
red p65/RelA fluorescence, the ratios of the green fluorophores were determined. 
The next graph shows that GFP does not significantly responds to IκB 
overexpression (column 1 & 3 Figure 4.26). It is more or less strongly localized in 
the nucleus, unlike HSC70-GFP which is severely affected by IκB. Its nuclear level 
is strongly reduced (column 2 & 4, Figure 4.26, P<0.01, Newman Keul's test). 
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Figure 4.26: Relative HSC70-GFP / GFP fluorescence 
4x10
6
 HEK293 FT cell were seeded in a six well plate and transfected 
with 4 µg of total DNA per well. The DNA mixture was composed of 
1 µg FPred-p65 and if indicated 2.8 µg GFP or HSC70-GFP and/or 
100 ng IκB expression plasmid complemented with empty expression 
vector. After 24 h of expression the cells were fixed, embedded and 
observed in confocal microscopy. The mean fluorescence of GFP in the 
nucleus and the whole cell was recorded and the ratio calculated. Sample 
sizes are -/GFP n=36, -/HSC n=46, IκB/GFP n=53, IκB/HSC70 n=37. 
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4.7 In vivo nuclear localization assay 
In the former assay it was observed that the co-transfection of HSC70 besides 
auxiliary p65/RelA in unstimulated HEK cells, equipped with a high endogenous 
NF-κB activity, shows a significantly higher level of nuclear p65/RelA than a 
transfection without HSC70. This is an indication that HSC70 is involved in NF-κB 
transport. If this transport / import system is important for NF-κB signaling due to 
the canonical pathway, this must be proven in a in vivo experiment. In this 
experiment, the NF-κB signaling was induced by a TNFα stimulus. The nuclear 
localization of NF-κB was monitored by expression of an FPred-p65/RelA fusion 
protein as described in the in vitro experiment. We compared cells transfected with 
HSC70-GFP fusion protein and GFP as control group. The green fluorescence was 
also used to monitor a potential nuclear co-localization. As the endogenous NF-κB 
activity of HEK293 FT and their high base level of nuclear NF-κB would have 
impeded the measurement of a nuclear NF-κB increase, all cells were transfected 
with IκB in a small copy number. This strongly reduced the basal amount of nuclear 
p65/RelA. For technical reasons, no zero value was measured. This is possible 
because it is reported for MEFs that the major effects of the TNFα stimulus take 
place after 10 to 30 minutes after treatments [197]. This was verified for HEK293FT 
in a pretest. First, the cells were stimulated with TNFα and afterwards a selected cell 
or cell group is observed by flourescence microcopy for 40 min at 37°C. 
The result of this experiment is presented in two figures and two charts. Figure 4.27 
exemplarily shows two cells. One was transfected with GFP, the other one with 
HSC70 GFP. They are displayed 10 and 40 minutes after TNFα treatment. Both cells 
were photographed using a red fluorescence filter for FPred and a green one for GFP. 
The merge image is shown below. Comparing these two cells, no time dependent 
increase in nuclear p65/RelA is detectable. Furthermore, there is no change in GFP 
or HSC70-GFP localization, but the nuclear p65/RelA level is conspicuously lower 
in the HSC70-GFP transfected cells. Additionally, the p65/RelA seems to aggregate 
by time. 
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Figure 4.28 confirms the observations, that HSC70 transfected cells contain less 
nuclear p65/RelA. It is also visible that there is no time dependent, clear increase in 
nuclear p65/RelA, but the aggregation of red fluorophore FPred-p65/RelA increases 
by time. 
 
  
Figure 4.27: In vivo nuclear localization exemplary overview 
HEK293 FT cells were transfected with Turbofect™ and HSC70-GFP or GFP, 
FPredp65 and IκBα. They were cultivated on chamber slides. 24 hours after 
transfection, the medium was replaced by 37°C prewarmed Tyrode’s buffer and the 
cells were stimulated with 25 ng/ml TNF at time point zero. The fluorescence of 
FPredp65, HSC70-GFP or GFP was observed under a confocal microscope 
tempered at 37°C. 
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Figure 4.28: In 
vivo nuclear 
localization of 
p65/RelA 
HEK293 FT 
cells are trans-
fected with 
Turbofect™ 
and HSC70-
GFP or GFP, 
FPredp65 and 
IκBα. They are 
cultivated on 
chamber slides. 
24 hours after 
trans-fection, 
the medium is 
replaced by 
37°C prewar-
med Tyrode’s 
buffer and the 
cells are stimu-
lated with 
25 ng/ml TNF. 
The fluores-
cence of 
FPredp65 is ob-
served under a  
confocal microscope. The microscope is placed under a 37°C tempered tent. This 
fi-gure shows the fluore-scence of FPred p65/RelA of exemplary cells co-
transfected with GFP (upper four rows) and HSC70-GFP (lower four rows). 
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The statistical evaluation of the fluorescence presented in Figure 4.29 approves the 
observations from Figure 4.27 and Figure 4.28. There is no significant increase in 
nuclear localization of p65/RelA by time. However, the nuclei of the HSC70-GFP 
transfected cells (column 4, Figure 4.29) contain significantly less p65/RelA than the 
GFP transfected control group after 40 minutes (column 2, P<0.05, Newman Keul's 
test). Figure 4.30 shows no significant variations in HSC70 or GFP distribution, but 
there seems to be a trend to a higher nuclear localization with enduring exposure to 
the test conditions. 
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Figure 4.29: Statistic of the in vivo nuclear localization of FPred-p65/RelA 
HEK293 FT cells were transfected with Turbofect™ and HSC70-GFP or GFP, 
FPredp65 and IκBα. They were cultivated on chamber slides. 24 hours after 
transfection, the medium was replaced by 37°C prewarmed Tyrode’s buffer and 
the cells were stimulated with 25 ng/ml TNF. The fluorescence of FPredp65 was 
observed under a confocal microscope. The microscope was placed under a 37°C 
tempered tent. The mean Fluorescence of FPredp65 was recorded in the nuclear 
region and the whole cell. The Fluorescence ratio of these ROIs was used for data 
analysis. Sample sizes are GFP/10 min n=10, - GFP/40 min n=10, HSC/10 min 
n=6, HSC/40 min n=6. 
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Figure 4.30: Statistic of the in vivo nuclear localization of HSC70-GFP 
HEK293 FT cells were transfected with Turbofect™ and HSC70-GFP or GFP, 
FPredp65 and IκBα. They were cultivated on chamber slides. 24 hours after 
transfection, the medium was replaced by 37°C prewarmed Tyrode’s buffer and 
the cells were stimulated with 25 ng/ml TNF. The fluorescence of FPredp65 was 
observed under a confocal microscope. The microscope was placed under a 37°C 
tempered tent. The mean Fluorescence of GFP or HSC70-GFP was recorded in 
the nuclear region and the whole cell. The Fluorescence ratio of these ROIs was 
used for data analysis. Sample sizes are GFP/10 min n=10, - GFP/40 min n=10, 
HSC/10 min n=6, HSC/40 min n=6. 
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5 Discussion 
5.1 Expression of p65/RelA in E. coli is inefficient in reason of differential 
codon usage 
The p65/RelA sequence of the fusion protein GST-p65 was encoded by a human 
cDNA. The codon usage of this sequence is different to E. coli. This means that the 
bacteria may have only a few tRNA to read out some codons and to translate them to 
an amino acid, because this specific AA is usually encoded by another triplet in E. 
coli. A rare codon may lead to a spontaneous stop of the translation. The GST-p65 
fusion protein was only expressed in c-terminal truncated forms. This truncation 
correlates with the appearance of rare codons in E. coli. These rare codons are used 
in less than 1% of all occasions to encode an amino acid by its specific codons. So it 
is probable that the truncated forms with about 60, 50 and 35 kDa are created by 
translation stops evoked by rare codons. This difficulties could be dealt with by using 
E. coli strains supplemented with additional tRNA genes like BL21-CodonPlus-RIL 
and BL21-CodonPlus(DE3)-RIL, but the number of additional tRNA is limited. The 
mentioned strains have increased tRNA levels for the arginine codons AGA and 
AGG, the isoleucine codon AUA, and the leucine codon CUA, but not for the 
arginine codon CGG [201]. Another possibility to express GST-p65 is the codon 
optimization of the coding sequence, but because of the successful 
immunoprecipitation with an antibody against p65/RelA, the sc-8008 from santa 
cruz, the expression of GST-tagged p65/RelA was not pursued any longer. With GST 
and GST-IκBα on hand, there are useful tools for the search of IκBα interactors. 
 
 
5.2 A protocol for the search for p65/RelA interactors from porcine tissues 
has been established 
p65/RelA interactor were purified by co-immunoprecipitation for brain extracts and 
identified by mass spectrometry after SDS gel separation. The protein input used for 
immunoprecipitation and mass spectrometric analysis was altogether soluble, 
ensured by ultracentrifugation. This is important to avoid false positive results by 
insoluble proteins which may be co-purified during the immunoprecipitation. Any 
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protein identified by mass spectrometry should have a direct or indirect interaction to 
the NF-κB subunit RelA. But while false positives could be decreased by extract 
preparation, isotype controls or by the increase of the score, there will always be 
false negatives or interactors which could not be detected. This is a result of the 
limited sensitivity of the method. The signal strength of the mass/charge peaks in the 
mass spectrum and therefore the probability of a valid protein identification depends 
on numerous parameters. These are among others the strength of interaction, the 
individuality of the tryptic fragment pattern, the concentration of the interactor and 
the complexity of the analyzed sample. The strength of interaction was improved by 
the use of the cross linking agent DSP. The fragment pattern after digestion with 
trypsin is protein specific and could not be optimized. 
The complexity of the sample is determined by the pre mass spectrometry separation, 
like the performed gel electrophoresis. For further reduction of the complexity, two 
different methods are recommended: Two dimensional electrophoresis (isoelectric 
focusing and SDS-PAGE) instead of simple one dimensional SDS-PAGE or an 
additional sensitive size exclusive chromatography. Due to the about tenfold increase 
in sample requirement using 2D gel electrophoresis compared to the 1D 
electrophoresis, for an equivalent intensity after coomassie staining, the second way 
was chosen. Besides the MALDI-MS, a combined liquid chromatography ESI-
MS/MS was performed. This allows a very precise size exclusive separation of 
proteins even with similar molecular weight. This enables for example the detection 
of HSP90AA1 beneath dynamin 1. The less complex samples lead to more simple 
spectra and higher scores. The threshold for protein scores was increased from 56 to 
80 using liquid chromatography. This increases the overall reliability of results from 
the improved mass spectrometry method. 
To guarantee a concentration of interactors as high as possible, porcine brain tissue 
extract was used as a source for neuronal NF-κB interactors. This source delivered a 
much higher protein yield, concentration, and as well as total mass than the mouse 
tissues (cf. Table 4.5). Using porcine extract, it was possible to use the same protein 
input for IP as suggested by Ilja Mikenberg [153] in a high concentration. The four 
different protocols tested for the extraction of pig brain tissues only lead only to 
small differences in concentration and total yield (cf. Table 4.5). The content of 
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p65/RelA was tested by an anti p65/RelA antibody, scheduled for the subsequent 
immunoprecipitation (Figure 4.8). 
The binding of the antibody is optimal in the extract derived from the so called white 
matter of the brain, whose name derives from the myelin of axons. This tissue is 
mechanically enriched by their major toughness. The high p65/RelA binding using 
this preparation could be a hint for a high degree of p65 transport. The p65/RelA 
level in whole cell extract, including the nucleus, is comparatively lower. It is only a 
hint, but no evidence, because no p65/RelA concentration is measured, but a ratio 
p65/RelA binding per 20 µg loaded total protein. Variation in local total protein 
concentration, especially in very small areas like the synaptosomes, does not permit 
to conclude concentration differences from p65/RelA mass ratio. This might be a 
reason for the low signal of p65/RelA in synaptosomal extracts, although it is known 
that p65 is transported from the synapse. However, it is not clearly understood how 
the synaptosomal p65/RelA is generated - maybe by anterograde transport or by 
translation in synaptosomal polyribosomes [200]. There is also less knowledge about 
the turn over. The more intense signal of p65/RelA observed using extract of frozen 
whole brain compared to fresh tissue may be related to an improved cell lysis 
including nuclei by freezing. This fits to the higher total protein concentration in 
frozen extracts. The murine extract only shows a weak response to the anti p65/RelA 
antibody, which could be related to different species. Overall, the axon enriched 
porcine brain extracts are the most promising. They show a high p65/RelA binding, 
deliver high yields, promise to preferentially provide interactors in transport and they 
are not frozen, which might destroy preformed transport complexes. 
The use of porcine sample material brings a new problem with it. Because the pig 
genome has not been fully sequenced, the mass spectrometric data has to be aligned 
to a human data base. Although humans and pigs are phylogenetical closely related, 
the differences in human and porcine protein sequence lead to differences in peptide 
masses. The porcine peptides, whose mass differ from the corresponding human 
peptides, cannot be detected. This provokes the effect that very conserved proteins 
are easily detected and less conserved ones are not. The detected cytosolic heat shock 
protein 90kDa alpha, class A member 1, short transcript shows for example 99% 
similarity in the amino acid sequence between human (homo sapiens) and pig (sus 
scrofa). Additionally, most of the sequential differences are located in one small 
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region from AA 259 to 284. For the NF-κB subunit RelA, the similarity is only 94%. 
This might be a reason why the last protein, even though primary precipitated, could  
not be found. Nevertheless, the detection of proteins like the mentioned HSP90 with 
reliable high scores or the detection of the immunoglobulin light chain fragment of 
the anti p65/RelA capturing antibody suggests the trustiness of the method. 
 
 
5.3 p65/RelA interactors are part of the endocytosis network 
Three proteins which are detected by mass spectrometry, enlisted in Table 5.1: 
p65/RelA interactors detected by MS are involved in the endocytosis network. This 
proteins are clathrin, dynamin and the heat shock cognate 70 (HSC70 or HSPA8) 
[188]. Other components are related to the filament system like actin, tubulin and the 
abundant neurofilament light polypetide (NEFL). This leads to the question if there is 
a connection of endocytosis and signalling combined with retrograde transport of 
NF-κB. During clathrin dependent endocytosis cargo molecules are included into 
vesicles surrounded by a cage of the polymerized coat protein clathrin [47]. Clathrin 
is directed via the multimeric cargo adaptor protein AP1-4 [55, 54, 90, 167 180] or 
the neuron specific, monomeric assembly proteins auxillin and AP180 [2, 171]. The 
formation of clathrin coated vesicles (CCV) is dependent on dynamin [196]. CCV 
form during endocytosis, by the assembly of dynamin into helical structures at the 
neck of clathrin-coated buds [205]. The hydrolysis of GTP by the GTPase activity of 
dynamin triggers a conformational change and constricts and pinches off the bud 
neck membrane [203]. The chaperone and ATPase HSC70 is needed for uncoating 
the constricted CCV. Recruited by APs, it unhinges clathrin from the polymer coat 
under ATP hydrolysis [103]. HSC70 also binds to free clathrin to inhibit spontaneous 
polymerization [103]. Our mass spectrometry results suggest that each of this 
endocytosis network proteins and the NF-κB subunit RelA are arranged closely 
together to certain, but probably different time points. The benefit of such complexes 
is not yet explored. 
A possible link between the endocytosis network and NF-κB is the fact, that both 
may be activated by the same stimulus. As previously described, the nerve growth 
factor (NGF) activates via binding on the p75 neurotrophin receptor (p75
NTR
) NF-κB 
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in neurons [101]. For motor neurons, it has been observed, that the retrograde 
transport of the same receptor upon ligand binding depends on clathrin mediated 
endocytosis, in a way that only p75
NTR
 from clathrin coated pits can be directed to 
retrograde transport [50]. Both signals, neurotrophin activated NF-κB transport and 
clathrin dependent p75
NTR
 transport, could be part of a signal cascade which ensures 
a specific response by this combination. The observed arrangements could either take 
place during the activation initiation of both pathways or during transport. 
Microtubular transport is also reported for CCV [60, 174]. Furthermore recent 
publications suggest that endocytosis may be required for NF-κB signalling. It has 
been found out that the Toll like receptor signalling, employing the Rel homolog 
dorsal is dependent on endocytosis in drosophila. It is estimated that the receptor 
signaling takes place from endocytotic compartment rather than the plasma 
membrane [138]. Wherever NF-κB and endocytosis proteins are connected, there 
might be a powerful key position for the regulation of the signaling cascade. 
Potential regulators could be the BAG (Bcl-2-associated athanogene) proteins. The 
best characterized protein is BAG-1, which functions as a nucleotide exchange factor 
for HSC70. It triggers substrate unloading from the chaperone. It contains an 
ubiquitin like domain and therefore is located next to the proteasome. BAG-1 
interacts with the carboxyl terminus of HSC70 interacting protein (CHIP). The last 
protein can recruit ubiquitin ligase, so the complex is able to direct substrates to the 
proteasome, label them for degradation and release them from the chaperone [5]. 
Interestingly, another member of this family, BAG-4 equipped with a minimal Bag 
domain of two thirds of BAG-1 length modulates HSP70 and HSC70 chaperone 
activity, too [31, 198]. This protein is also known as silencer of death domain 
(SODD) released from the TNF-R during TNF induced NF-κB signalling [104] It is 
not known whether SODD is also associated to other receptors of the TNF-R super 
family, but at least for TNFR1, BAG4/SODD links the NF-κB activation to 
endocytosis by the opportunity to modulate the activity of HSC70 uncoating the 
endocytosed vesicle. 
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Table 5.1: p65/RelA interactors detected by MS 
Protein 
MALDI-
MS 
LC-ESI-
MS/MS 
Relation to p65/RelA or 
retrograde transport 
beta 5-tubulin √ 
 
microtubule subunit 
beta actin √ 
 
microtubule related filaments 
clathrin, heavy polypeptide (Hc) √ 
 
endocytosis network 
dymanin 1 √ √ endocytosis network 
heat shock 70kDa protein 8 (HSC70) √ √ endocytosis network 
hepatoma-derived growth factor, related 
protein 3 
√ 
 
similar effects, retrogr. cargo 
dihydropyrimidinase-related protein 2 
 
√ transport regulator 
HSP90 alpha (cytosolic), class A member 1 
 
√ retrograde transport (e.g. GR) 
HSP90 alpha (cytosolic), class B member 1 
 
√ retrograde transport (e.g. GR) 
immunoglobulin light chain (fragment) 
 
√ anti p65/RelA fragment 
NEFL; neurofilament, light polypeptide √ √ microtubule related filaments 
tubulin alpha 6 √ √ microtubules subunit 
 
 
5.4 Heat shock proteins / chaperone based trafficking 
Besides HSPA8 which could be related to the endocytosis network, the heat shock 
protein 90 kDa is found as an p65/RelA interactor in mass spectrometry (Figure 
4.11). Heat shock proteins are the most frequent proteins in unstressed cells. For 
example, HSP90 constitutes 1-2% of cytoplasmic protein. Their function is not 
limited to housekeeping like the control of activity and turnover, but it has been 
known that they also interact and transport signal molecules as transcription factors 
or kinases [172]. There are five genes encoding different forms of HSP90. The heat 
shock protein 90kDa alpha (cytosolic), class A member 1 (HSP90AA1) was detected 
here. 
Our expectations to observe NF-κB transport are confirmed by the finding of tubulin, 
which provides the essential tracks, and the associated neuro- [155] and actin 
filaments. Fortunately, HSP90 is known to play a role in the transport of transcription 
factors such as the glucocorticoid receptor (GR). The glucocorticoid receptor 
interacts with HSP90 [186]. The in vivo function of the receptor is dependent on 
HSP90, which was shown by induced expression [168], mutation [165], and 
pharmacological inhibition by Geldanamycin of HSP90 [214]. Besides the 
glucocorticoid receptor, it interacts with at least 20 other transcription factors [172], 
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among them sexual hormone receptors [105, 193] and the SV40 large T antigen 
[156]. So it seems plausible to assume that HSP90 also plays a role in the NF-κB 
transport. 
There are some connections in GR and NF-κB signaling. They share interactors, 
namely HSP90 and a 70 kDa heat shock protein. Furthermore they show a physical 
association in IP and functional antagonism [176]. While NF-κB is related to 
immune and inflammatory responses in many cases, glucocorticoids are connected to 
anti inflammatory activities. It is reported that the activation of the GR with 
dexamethasone (ligand) reduces the activity of the interleukin 6 promoter driven by a 
RelA enhancer. Vice versa activation of the mouse mammary tumor virus promoter 
by a combination of dexamethasone and glucocorticoid receptor is inhibited by 
overexpression of p65 [176]. 
Therefore it might be useful to have a closer look on a model for GR transport 
invented by William B. Pratt et al. [172]. This model suggests that the assembly of 
the transport complex takes places in two major steps. In the first step, the GR forms 
a "primed" complex with the heat shock protein, ATPase HSP70 and the 
cochaperone HSP40 in an ATP dependent manner [159]. HSP40 as well as HSP70 
with bond ATP can bind to GR alone [87, 116]. The order of assembly is unknown, 
but HSP70-ADP/GR must be stabilized by HSP40 [116]. The hydrolysis of ATP may 
be responsible for partially opening the GR binding cleft and priming the complex 
for the second step. In the second step, a HSP90 dimer bond to the HSP organizing 
protein (HOP) enters the complex. HOP preferentially binds to the ADP-bound form 
of HSP90 [106]. HOP mediates the interaction of HSP70 and HSP90 via two 
tetratricopeptide repeats (TPR) [43, 131], which is a protein-protein interaction 
module [25]. Dependent on ATP, the binding cleft of GR is opened for ligand 
binding [116]. The now ATP bond HSP90 releases HOP and binds to p23, an acidic 
23-kDa protein [108], which only binds to the ATP-dependent conformation of 
HSP90 [202] and stabilizes receptor-HSP90 heterocomplexes after conversion to the 
steroid-binding state [59]. HSP70 may be also released by the mature complex and is 
not found in an stoichiometric manner. HSP90 of the mature complex is connected to 
the transport machinery via immunophilin (see Figure 5.1). The retrograde transport 
of GR is based on the motor protein dynein.   
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Transport of the Glucocorticoid receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon arrival at the nuclear pores, the receptor-HSP-immunophilin complex crosses 
the membrane by importin-dependent facilitated diffusion and mediates further 
receptor cycling [173]. An involvement of importin in the GR complex transport has 
not yet been researched and importin is not regarded in the model. Because the 
transport, not only the nuclear import, of NF-κB depend on its NLS [81, 82], the 
model must be expanded for NF-κB. 
  
Figure 5.1: Transport of the GR 
Pratt, W.B.; Galigniana, M.D.; Harrell, J.M.; DeFranco, D.B. (2004) Cellular Signalling 16:857–
872 [173]. 
Microtubular transport of the ligand bond Glucocorticoid receptor (GR) HSP90 
heterocomplex. The complex, also containing p23, is connected to the 
intermediate chain (IC) of the motor protein dynein by immunophilins (IMMs). 
The interaction to HSP90 is mediated by the IMMs TRP domain, while it links to 
dynein or more exact to the dynactin complex via its PPIase domain [83]. The 
dynein associated dynactin complex and the dynein light chains are not shown. 
Dynein transports its cargo via its two heavy chains (HC), which have the 
processive motor activity, along microtubules in a retrograde movement to the 
nucleus. The broken line around HSP70 indicates that it is not found in the 
transport complex in a stoichiometric manner. 
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5.5 RelA interacts with CRMP2 and HDGFRP-3 
In mass spectrometry, two other components were found: The hepatoma-derived 
growth factor, related protein 3 and dihydropyrimidinase-related protein 2 
(DPYSL2), also known as collapsin response mediator protein 2 (CRMP2). Both 
proteins play important roles in brain development. 
The family of hepatoma-derived growth factor contains six members. The hepatoma-
derived growth factor related protein 3 is, in contrast to the other members, 
exclusively expressed in the nervous system, predominantly in neurons [66]. Due to 
its high regulation during brain development it is estimated that HDGFRP-3 has 
other functions besides its ability to steer mitogenic activity, as for example axon 
guidance or synapse formation [1]. Interestingly, similar effects are connected to NF-
κB activity [111]. HDGFRP-3 underlies retrograde nuclear transport and it contains a 
bipartide basic NLS which consists of the basic motif, KRKNEKAGSKRKK 
(residues 136–148) [97]. This corresponds to the NLSs of a NF-κB dimer. For 
example, the RelA NLS complies to the consensus sequence K-(K/R)-X-(K/R) in 
which X is any amino acid with the sequence K301RKR304 [15, 134], while p50 has 
the sequence RKRQR [24]. It could be shown in mutation assays that HDGFRP-3 
nuclear localization depends on its bipartide NLS [65]. So it quite probable that they 
use the same transport machinery including importin-α dependent nuclear import. As 
NF-κB and HDGFRP-3 activity are both related to brain development and synaptic 
plasticity, this transport system could be a natural target for developmental 
regulation. 
The second interactor CRMP2 is also very important for neuronal development, 
especially neurite growth. CRMP2 promotes neurite growth by microtubule 
assembly [11, 74]. Furthermore, it regulates microtubular transport by a N-terminal 
Kinesin-1 and a dynein HC binding domain found in the opposite of the protein in a 
3D model [9]. Via kinesin and a cargo binding capability, it may transport other 
proteins in positive direction [121, 12, 209]. The dynein binding domain also blocks 
the motility of the motor protein. Thereby it may promote transport to distal regions 
[9]. In addition, it has been found that a c-terminal truncated form of CRMP2 is 
transported to the nucleus. The truncation is generated by posttranslational 
processing and it is believed that it unmasks a short NLS, which is enclosed in the 
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full length protein. The nuclear localization of the processed CRMP2 results in the 
inhibition of neurite outgrowth [181]. The mechanism is yet unknown. 
 
 
5.6 Co-immunoprecipitation suggests GR analog NF-κB transport complex 
In our co-immunoprecipitations, a physical interaction of RelA/p65 and HSC70 alias 
HSPA8 has been verified using the cross linking agent DSP (cf. Figure 4.16: 
p65/RelA and HSP CoIP cross linked). DSP can only link proteins with lysin ore 
arginine residues in a close range of 12 Å or less. The constitutive Hsc70 and 
inducible Hsp70 are generally considered, with rare exceptions [8], to be equivalent 
proteins exhibiting functional similarities [36]. However, although the overall 
structures of these two chaperones are almost identical, they do differ in some 
specific areas [149]. Their carboxyl-terminal domains (amino acid 510–641) differ 
considerably in structure (“only” 69% amino acid identity). This domain may 
stabilize the peptide-binding pocket more efficiently in Hsp70 than in Hsc70 and 
therefore may regulate the access of substrates to the peptide-binding pocket 
differently. 
Based on the similarities, both heat shock proteins may be exchangeable and our 
found HSC70/HSPA8 may be also participate in the assembly of a transport 
complex. Furthermore, it has been shown that a random mutation in the ATPase 
domain impedes the interaction with RelA/p65 (cf. Figure 4.17: Decrease of 
p65/RelA interaction by HSC70 Phe68→Cys mutant). This correlates with the GR 
transport model in which HSP70 may bind the cargo independently from the type of 
bound nucleotide (ADP or ATP), but the further assembly of the complex, which 
grants stable interaction, needs HSP70s ATPase activity. It is also observed that the 
presence of brain extracts has a stabilizing effect on the HSC70 RelA/p65 
interaction. This effect is not strong enough to achieve an interaction without the use 
of cross linking agent, but qualitatively strengthens the cross linked interaction (cf. 
Figure 4.19: Neuronal proteins influence p65/RelA and HSC70 interaction). This 
may be related to co-factors similar to the co-chaperone HSP40 or rather HOP and 
HSP90 from the GR-transport model. It could be estimated that some of these 
proteins, excluding the abundant HSP90, are enriched in neuronal extractions. The 
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HEK293 FT cells used for the expression of the observed interactors will probably 
express these co-factors at a lower level than neurons or not even at all. 
The interaction of HSP90 to RelA/p65 detected by mass spectrometry could not be 
verified by co-immunoprecipitation (cf. Figure 4.16: p65/RelA and HSP CoIP cross 
linked). Nonetheless, the negative result in co-IP also cannot falsify the prior result, 
because it is still possiblethat an interaction is just too weak to be detected in co-IP 
even if a cross linker is used. It is known that HSP90 is unable to bind biologic 
substrates such as steroid receptors on its own and that it requires the assistance of 
several other proteins [172]. Maybe the supply of this chaperones, co-chaperones, 
adaptor proteins and nucleotides is not sufficient for the interaction. It is also 
important to notice that in the GR transport model, the association of HSP90 to the 
transport complex is not the first, but the second step. 
In Figure 4.21 it was analyzed what kind of influence the presence of ATP and the 
temperature has on the interaction of RelA/p65 and HSC70. The result was quite 
surprising: while the addition of ATP does not show distinct effects, the increase in 
incubation temperature during IP makes the use of cross linker obsolete. 
Interestingly, also the ATP dependent p23 binding to HSP90 during the formation of 
the GR transport complex is improved at higher temperatures (30°C) by supporting 
the exchange of ADP by ATP in an active process [202]. However in this model, the 
binding of p23 goes along with the release of HOP and a part of HSP70. So the 
mechanism in RelA/p65 complex association must be differing, because elevated 
temperature increases the binding of HSP70 analog HSC70. Maybe also the first step 
analog to HSP40 and HSP70 binding, which is also ATP dependent, can be improved 
by increasing the temperature. 
The poor effect of ATP may be related to basal level of ATP sufficient for 
interaction. The removal of basal ATP with apyrase may increase differences in 
binding behavior. Only with 1 mM additional ATP, there seems to be an increase in 
interaction. The double bands visible in the sample with no additional ATP and with 
1 mM additional ATP may be based on by different levels of phosphorylation. On 
the one hand, phosphate groups improve the motility in gel electrophoresis by their 
high negative charge, on the other hand they block the binding of the hydrophobic 
fatty acid residue of SDS and thereby also impede the protein motility. The overall 
effect depends on the location of the phosphorylation.  
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5.7 HSC70 alias HSPA8 promotes RelA/p65 nuclear localization 
After it has been shown that the heat shock cognate 70 kDa protein is an RelA/p65 
interactor, it suggests itself to examine the biologic relevance of this interaction. In 
addition, the hypothesis of the participation of HSC70 in RelA/p65 signaling needed 
confirmative data. Therefore two strategies were pursued: A luciferase promoter 
assay and a nuclear localization assay by immunofluorescence. The luciferase assay 
inquires the effect of HSC70 on NF-κB dependent gene transcription, while the 
nuclear localization assay explores HSC70 effects on the distribution of RelA/p65 
between nucleus and cytoplasm. 
The luciferase assay displays the NF-κB activity by the activity of the luciferase 
enzyme encoded by a reporter gene equipped with a NF-κB promoter. The assay has 
shown that HSC70 promotes NF-κB activity by the definitive positive slope in 
Figure 4.23 and the significant fold change in Figure 4.24, but only in presence of 
overexpressed RelA/p65. The effect of HSC70 overexpression seems to be low 
compared to RelA/p65 overexpression. The reason for this reduced effect is that we 
monitor overexpression based on an unknown basal level of expression. At our 
chosen zero reference point, only the overexpression is zero, not the overall 
expression. We can be sure that the basal expression of HSC70 is much higher than 
those of RelA/p65, because the first is an abundant heat shock protein and the last a 
strictly regulated transcription factor. The relative increase in HSC70 expression, 
relative to basal expression, is much smaller compared to RelA/p65. This is also the 
explanation for the fact that there is no effect of HSC70 overexpression without co 
transfection with RelA/p65. Without the last, there is an excess supply of HSC70 
which is not able to find enough RelA/p65 for interaction. Only by overexpression of 
RelA/p65, the role of the limiting factor passes over to HSC70. 
If increasing levels of overexpression are compared, the HSC70 level demonstrates a 
similar effect for NF-κB activity like the RelA/p65 expression. So four-fold 
overexpression of HSC70 increases the NF-κB activity by two fold (cf. Figure 4.23: 
HSC70 increases NF-κB activity, 100 ng  and 400 ng HSC70) and a five-fold 
increase in p65 overexpression increases the NF-κB activity also by two-fold 
(column 3 & 4, Figure 4.22). This means that HSC70 decisively participates in NF-
κB activation. 
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The HSC70 dependent increase in NF-κB activity should be reversible by addition of 
deoxyspergualin (DSG). DSG binds with high affinity to HSC70 and increases its 
ATPase activity, it also inhibits nuclear localization of HSP70 and is correlated with 
a decrease NF-κB activity [162]. The mechanism is not yet understood. Our data in 
Figure 4.24 shows no difference in NF-κB dependent transcription after DSG 
treatment independent from HSC70 expression level. Although unexpected, there are 
two plausible explanations: The assay is inappropriate due to the long expression 
period (24 h) during which DSG is degraded or DSG interferes in transport, but 
translocation is diffusion dependent in the chosen HEK293 cells. 
After having proven that the overexpression of HSC70 stimulates the transcription of 
NF-κB target genes, it remains to clarify how this effect is generated. As described 
above, we assumed a participation of HSC70 in NF-κB transport and a nuclear 
localization comparable to the glucocorticoid receptor model. This model includes 
nuclear import and intra nuclear functions of the receptor-HSP complex [173]. That 
means that although our nuclear localization experiments is not suitable to prove 
participation of HSC70 in tubular transport - transport is diffusion dependent in non 
neuronal cell - involvement in nuclear localization would substantiate suspicion of its 
relevance for transport, because the ability to pass the nuclear membrane is a 
prerequisite for being part of a transport complex. 
There are previous publications about the nuclear translocation of HSC70 in response 
to oxidative stress, during apoptosis [49] and heat shock [123], which are typically 
accompanied by NF-κB activation. It is assumed that HSC70 is retained in the 
nucleus by its substrates and associates with nucleolar proteins [123]. This 
assumption was affirmed by the characterization of three nuclear transport signals. 
The first is a typical basic nuclear localization signal with the sequence 
246
KRKHKKDISENKRAVRR
262
, located in the N-terminal ATPase domain [48]. 
The others are a nuclear localization related signal NLRS and a nuclear export signal. 
These last two sequences are both localized in the peptide binding domain and 
interact inhibitory by themselves or bound protein substrate. Thereby, NLRS bound 
molecules may impede nuclear export. NLS as well as NLRS are sufficient for 
mediating nuclear import, but both regions are necessary to mediate a nuclear 
accumulation of HSC70, as observed for example during heat shock [129, 210]. It is 
Discussion  103 
also reported that the related HSP70 promotes NF-κB nuclear translocation by the 
expression of a HSP70-p50 fusion protein [72]. 
To validate the dependence of NF-κB nuclear localization on HSC70, we used to 
approaches: The localization of RelA/p65 and HSC70 as end point determination in 
permanent NF-κB active and repressed cells and an in vivo time course experiment 
after TNF-α treatment. The repression of NF-κB activity was achieved by IκBα 
overexpression in the first approach . The first approach delivered the result that in 
absence of IκBα, the nuclear localization of p65/RelA is slightly increased if HSC70 
is contemporaneously overexpressed (Figure 4.25., column 1&2). If RelA/p65 is 
inhibited by IκBα, there is a drastic change to nuclear localization of HSC70. These 
two observations perfectly support our hypothesis of HSC70 dependent NF-κB 
translocation. The relative exiguity of the first effect depends again on a level of 
basal HSC70, which is nearly sufficient to mediate the transport, and on the 
characteristic of an end time point determination. This means that we cannot observe 
potential differences in the translocation kinetics corresponding to HSC70 expression 
level and therefore, one molecule of HSC70 may translocate some RelA/p65 
molecules by and by. The last mechanism only plays a negligible role, through the 
retention of HSC70 by RelA/p65 as postulated in [123, 210] and observed in Figure 
4.26, column 2&4. Only this retention of HSC70 makes it possible to observe an 
increase in RelA/p65 nuclear translocation corresponding to HSC70 expression level. 
Although in principle, time course experiments are more trustworthy than snap shot 
experiments, the HSC70 independent induction of NF-κB could only be achieved in 
the first experiment, in which the transport equilibrium is reached. In this first 
experiment, there was a strong nuclear localization of RelA/p65 in absence of IκBα 
and a strong cytoplasmic localization in presence of IκBα. This well known 
correlation must be shown by the assay. However, the in vivo time course 
experiment does not show a nuclear localization of RelA/p65 in response to the 
employed stimulus (TNF-α). The statistical results (Figure 4.29) only display a small 
insignificant increase in nuclear RelA/p65 between 10 and 40 min after stimulation. 
According to recent publications, the translocation in response to TNF-α takes 
between 10-30 min and is completed after 40 min after stimulation [197]. A reason 
for this is probably the slight co expression of IκBα. On the one hand, the expression 
level of IκBα could be too high so that the activation of NF-κB by TNF-α is 
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inhibited. On the other hand, IκBα is necessary to prevent a nuclear localization of 
RelA/p65 in unstimulated cells as shown in the snap shot experiment. The 
overexpression by the fluorescence tagged RelA/p65 strongly increases the NF-κB 
activity. Without IκBα, there would not be a detectable TNF-α effect either. This 
means that a careful titration up to the appropriate IκBα level is necessary. It is quite 
probable that this aim has been overshot. While this explains the absence of a TNFα 
effect, one effect of HSC70 on Rela/p65 distribution is still visible: The HSC70-GFP 
retains RelA/p65 in the cytoplasm compared to the GFP transfected control. This can 
be evaluated as a sign of interaction and or of shuttling of RelA/p65 from the 
nucleus. It seems probable that HSC70 mediates nuclear im- and export of NF-κB, 
but the regulation is performed by other players as for example directly by IκBs. 
Another explanation for the strong nuclear depletion of RelA/p65 by HSC70 may be 
a potential interaction to IκBs. If HSC70 can also translocate IκBs, the RelA/p65 will 
efficiently be exported in presence of IκBα as we observed it. 
The in vivo time course experiment shows no significant differences in the 
localization of HSC70 compared to GFP, which can be also related to the poor 
induction. HSC70 and GFP seem to tend to more nuclear localization during the time 
course. This could be presumed , by reason of the slight reduction of cytoplasmic 
volume in response to stress. 
Some of these observed effects can also be related to the ability of HSC70 to export 
the nuclear import receptors of the importin-β family [126], but the nuclear 
localization of HSC70 itself and the IP results suggest a direct interaction of HSC70 
and RelA/p65 and a promotion of nuclear import. The nuclear interaction to the NF-
κB subunit to the HSC70s NES stands to the reason for nuclear accumulation of 
HSC70. 
 
 
5.8 HSC70 interacts with NF-κB in a transport model 
We have proven that HSC70 interacts with RelA/p65, affects its nuclear 
translocation and modulates the activity of the transcription of NF-κB target genes. 
We also know about the dynein dependent axonal transport of NF-κB, which shows 
parallels to glucocorticoid receptor transport, but there are also more hand-tight 
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connections: As mentioned above the NF-κB and the GR show a functional 
antagonism and a physical association [176]. This physical association, detected by 
Although Ray A. et. al., could be misinterpreted as a direct interaction. It could be 
also an indirect one mediated by heat shock proteins. The interaction study was 
performed by co-IP of cell free, in vitro synthesized RelA/p65 and GR, but the 
translation system uses reticulocyte extract, which contains high amounts of heat 
shock proteins [172]. Species differences between HSPs from reticulocyte extract, 
usually rabbit, and human RelA/p65 and GR probably do not affect the interaction by 
reason of the high conservation of HSPs. So the association may be a sign of 
potential co-transport. At first view, a co-transport seems contradictory to the 
observed functional antagonism. A competition or inhibitory interaction is rather 
expected. However, if we assume a competition for binding capacities in transport, 
we have to consider that this transport cannot be limited to one molecule per 
transport complex (v.i.). Therefore in a competition between cargo like RelA/p65 
and GR the loading ratio is shifted. A state of exclusive transport of only one 
compound, if it exists at all, must alternate with a state in which both cargos are 
carried in varying numbers. 
Another reason to assume co-transport can be derived from the physical properties of 
the transport complex. The dynein motor protein can proceed in various step lengths 
from 8 to 32 nm. The motoric force is anti proportionally correlated to the step length 
and reaches gigantic peaks of up to 1.1 pN [141]. By this force, a few (1-4!) dynein 
units can move whole organelles [10] and are fast enough for axonal transport [143]. 
The cooperation of the four dynein heads is rather necessary to prevent dissociation 
and processive, fast movement than to generate extra force [144]. This motoric force 
is surely not limited to the transport of one GR. It can be assumed that the GR 
transport model shows only a part of a large transport complex. If this also included 
vesicle transport, it would efficiently exploit the capacity supplied by the dynein 
motor. 
NF-κB as well as vesicle transport may be induced by the same stimulus like the 
binding of NGF [50, 101] or EGF [62, 225]. Besides the full use of capacity, the 
co-transport of cytoplasmic proteins as NF-κB and vesicles may benefit from 
synergistic effects. For example, the recruitment of the motor protein may promote 
both, NF-κB and the vesicle transport. The coupling of NF-κB signaling and 
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endocytosis [138] has the same benefits on a subsequent co-transport. The 
characteristics of axonal transport cause that the cargos share the same destination 
over a long distance at least to the cell body. There we believe that collective co-
transport is the plausible, efficient way of neuronal transport. 
 The remaining question concerns the role of the cargo adaptors, which are necessary 
to contemporaneously bind different targets to one motor protein. Therefore it takes a 
complex of proteins that is capable of binding different cargos, supplying a 
connection to the motor protein and assembling to a docking scaffold. In the model 
presented by W. Pratt et al. [173], HSPs undertake the first two functions. The same 
applies to the dynactin complex. It directly binds to dynein and is the adaptor 
between dynein and HSP in an interaction chain (dynein - dynactin - immunophilin - 
HSPs - cargo) [83]. Dynactin also maintains further interactions with organelles via 
its Arp1 subunits and the protein spectrin [91, 161]. But although the dynactin 
complex is a large 1.1 MDa complex consisting of eleven subunits [119], there are 
no reports about additional oligomerization and therefore, the accessibility of the 
dynactin complex for cargo is limited. That means it cannot bind to a large number 
of cargo molecules directly or just by binary interactors. This function needs either a 
branched network of proteins which supports three or more interactions or a 
oligomer of proteins, maybe both. Figure 5.2 shows the confirmed part of the 
transport complex and illustrates the question for further cargo binding sides. 
 
 Figure 5.2: The dynein transport complex and the question for 
further cargo binding sides 
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HSP90 as well as HSC70 are reported to oligomerize. In both cases, oligomerization 
is dependent on ATP and is largely increased at an elevated temperature. But in 
contrast to HSP90 and HSP70 respectively, HSC70 forms oligomers at 37°C under 
in vitro conditions. Furthermore HSP90 multimers, dimers and oligomers, still show 
chaperone activity, while HSP70 and HSC70 lose their substrate binding capabilities 
upon oligomerizetion [8, 41]. A C-terminal domain of HSC70 is responsible of both 
self association or subtrate binding [69]. Beside this, the domain interacts with the 
ATPase domain and modulate its activity [20]. It has been proposed that the self 
association and oligomerization regulates the activity of the chaperone by 
constituting an inactive reserve. This stored HSC70 can be released by 
monomerization quickly. The equilibrium of monomeric and multimeric HSC70 is 
tightly controlled not only by substrate and ATP concentration, but also by protein 
co-factors [8]. Maybe the oligomerized HSC70 is not limited to its function as a 
reserve, but also as a scaffold protein in transport, while cargo interaction is mediated 
by HSP90. This hypothesis is substantiated by the fact that HSC70 forms aggregates 
with spectrin during translocation. This aggregates can be dissolved by addition of 
ATP [57]. Spectrin is known as the scaffold protein which mediates the interaction of 
dynactin and transported vesicles. The association of spectrin and HSC70 may 
provide a docking platform. At least it is a sign that HSC70 has function enduring 
transport and not only in transport complex formation. 
All together HSC70 is a pivotal player in cellular transport. It participates in loading 
the cargo on HSP90, as seen for the GR, and it may mediate nuclear import by its 
NLS. HSC70 is involved in processing of endocytosed and transported clathrin 
coated vesicle, too. Furthermore, it may serve as a docking platform to grant a larger 
number of cargo molecules access to the transport machinery. Therefore it might 
interact with spectrin, oligomerize, associated with HSP90 to form transport 
complexes. It also may recognize cargo NLS [98] or interact with importins by its 
own NLS [48] and therefore ensure NLS specificity as detected in NF-κB transport 
[153]. This detected and potential functions make HSC70 an important target for 
regulation. 
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6 Summary 
In this work, new NF-κB interaction partners were identified, among these the heat 
shock protein HSC70. For this protein, further interactions with the NF-κB signaling 
were explored and detected. The transcription factor NF-κB is an important 
regulatory element in a broad variety of cell processes. In addition to its well studied 
role in inflammation, in immune response, and in apoptosis it is known to steer the 
development of neuronal cells. In these cells with spacious signal pathways, active 
transport of NF-κB is indispensable. Mediators during this transport and subsequent 
nuclear import can be detected as NF-κB interaction partners. The identification of 
new interaction partner and therefore potential mediators in transport may help to 
improve and expand existing models. 
New NF-κB interaction partners were detected by immunoprecipitation of porcine 
brain extracts with a anti RelA/p65 antibody and subsequent mass spectrometric 
analysis. The porcine origin lead to the preferential finding of conserved proteins. 
The detected proteins are part of the endocytosis network, are filament compounds or 
play a role in intracellular transport. This includes the endocytosis network proteins 
clathrin, dynamin and HSC70, the filaments actin, tubulin and NEFL and the 
components of transport complexes heat shock proteins HSC70 and HSP90, the 
transport regulators CRMP-2 and the cargo HDGFRP3. The physical associated 
proteins detected by mass spectrometry may interact with NF-κB during one or some 
processes as for example signalling, transport, nuclear import or transcription 
activation. A reasons for the finding of players in endocytosis may be a conjunction 
of endocytosis and NF-κB signalling [138] or co-transport of vesicles and NF-κB. 
From the detected proteins the heat shock proteins are most promising candidates to 
be a cargo adaptor in NF-κB transport. The reason is that HSP are known to mediate 
the transport of other protein, especially the glucocorticoid receptor described by the 
group of W. Pratt [173] and they are capable of the binding of a broad variety of 
substrates. The interaction of RelA/p65 was tested in co-immunoprecipitation. While 
RelA/p65 interacts with HSC70 it does not with HSP90. The interaction is weak and 
only detectable in presence of a cross linking agent. The weak interaction of 
RelA/p65 and HSC70 can be increased by elevated temperatures (37°C) or the 
addition of brain extracts. We believe that the elevated temperature increases by 
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complex formation by the support the ATPase activity of HSC70. The beneficial 
effect of brain extract on the interaction indicates that some co factors or co-
chaperones participates in the interaction which are preferentially expressed in 
neurons. The HEK293 cell line used for the expression of the interaction partners 
lack this co-factors because NF-κB is diffusion dependent in this cells. This is an 
evidence for the participation of HSC70 in NF-κB transport and not only for nuclear 
import or other purposes for interaction. 
If the transport of NF-κB is comparable to GRs, HSP70 or HSC70 are employed in 
the transport complex formation while the "mature" complex contains two molecules 
HSP90 and only substoichiometric amounts of HSP70. If this is true, the absence of 
HSP90 in our IP complexes mean that we may monitor early, "immature" 
complexes. 
Next to its role in transport HSC70 is also known to effect nuclear localization of 
many targets. So we also tested its effect on RelA/p65 localization. We could show 
that HSC70 promotes the nuclear localization of free, non inhibited RelA/p65 and 
RelA/p65 in return retains HSC70 in the nucleus. In a luciferase assay we could 
show that this HSC70 increased NF-κB nuclear localization leads to a boost of the 
transcription of NF-κB target genes. This ability to mediate nuclear localization also 
improves the function of HSC70 containing transport complexes if they are present 
intra and extra nuclear, as described for GR. 
Finally we discuss the heat shock protein like HSC70 may be an important connector 
or regulator in a real in vivo transport complex, of which the proposed model of W. 
Pratt et. al. only describes a detail excerpt. So HSC70 is involved in many more 
processes than nuclear import and the loading of cargo onto small transport 
complexes. It is well known to mediated endocytosis, which connection to NF-κB is 
supported by our mass spectrometry data and which is a frequent starting point of 
transport processes. It may also be regulated by TNF-α stimulated NF-κB activation 
[31, 104, 198]. Furthermore HSC70 builds up aggregates with spectrin during 
translocation [57], which may serve as a docking platform in transport. This let us 
believe that HSC70 occupies a key role in transport processes, from plasma 
membrane to nucleus, which a broad variety of different functions. Therefore HSPs, 
especially HSC70, must be considered in future NF-κB transport models. 
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7 Outlook 
The RelA/p65 interaction can be further characterized by IP experiments. It is likely 
that the chaperone activity of heat shock proteins plays a role in the complex 
formation in transport. Our results suggests that a depletion of basal ATP is 
necessary to achieve significant effects on interaction strength by ATP. Furthermore 
we could not verify an interaction of HSP90 and RelA/p65 in co IP. As explained 
above this does not contradict or falsify an association, because It could be the 
caused by a very weak interaction. Maybe an increase in temperature to 37°C (no 
heat shock conditions) strengthens the association by promotion of the ATPase 
activity so an interaction can be monitored. This would apply to the GR model in 
which HSP90 binds after HSP70 prepared by anterior steps of ATP hydrolysis. The 
next step in co IP would be the establishment of a minimal system of complex 
proteins starting from the GR complex with HSC70, HSP40, HSP90, HOP and p23. 
Besides immunoprecipitation and western blotting new interaction complexes may 
be identified by mass spectrometry. Therefore complexes, containing RelA/p65, 
other cargos or potential mediators as HSPs, can be separated by native gel 
electrophoresis as for example blue native electrophoresis. The components of this 
purified complexes can be identified by liquid chromatography and tandem mass 
spectrometry. This would allow the research of HDGFRP-3 transport, which is 
believed to be co-transported with NF-κB in result of our mass spectrometric 
measurements. It would also be suitable to get more information about the character 
of CRMP2 / NF-κB interaction. 
As described the use of porcine sample material complicates the identification of less 
conserved proteins using a human data base for the analysis. The expansion of 
porcine data bases will make this obsolete and will enable a faster and better analysis 
of the data. 
Next to this, the participation of HSC70 in transport of NF-κB must be confirmed in 
vivo. In our workgroup, experiments are currently performed to verify NF-κB-HSP 
interaction or co-localization in neurons by "Duo Link". In this method antibodies 
coupled with nucleotide sequences are directed against the target proteins. Close 
proximity of the nucleotide sequences enables an amplification and a subsequent 
detection with fluorescence tagged oligonucleotides. The verification of in vivo 
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interactions could be achieved by labeling the interaction partners for FRET 
measurements, too. The best method to observe transport in neurons would be 
fluorescence recovery after photo bleaching (FRAP) in combination with the HSC70 
inhibitor DSG. 
Furthermore, it would be interesting to find out if NLS mutants of the GR undergo 
axonal transport or if this mutation inhibits it, because this has been shown for NF-
κB, but has not been investigated for GR. If both transport systems obey the same 
regulations, an assumed co transport is more likely. In this case, an expansion of the 
model for GR transport [173] would also be necessary, in which maybe HSC70 plays 
a role for NLS recognition. 
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9.3 GST-p65/RelA sequence coverage in MS 
 
coverage after mass spectrometry of GST-p65/RelA Sequence 
 
001 mspilgywki kglvqptrll leyleekyee hlyerdegdk wrnkkfelgl efpnlpyyid 
MS1                              ◄■■■■■■■►                            
MS2                    ◄■■■■■■■■►◄■■■■■■■►           ◄■■■■■■■■■■■■■■■ 
MS3                    ◄■■■■■■■■►◄■■■■■■■►           ◄■■■■■■■■■■■■■■■ 
MS4                    ◄■■■■■■■■►◄■■■■■■■►                            
MS5                    ◄■■■■■■■■►◄■■■■■■■►◄■■■■■■►   ◄■■■■■■■■■■■■■■■ 
MS6                    ◄■■■■■■■■►◄■■■■■■■►◄■■■■■■►   ◄■■■■■■■■■■■■■■■ 
MS7                    ◄■■■■■■■■►◄■■■■■■■►◄■■■■■■►   ◄■■■■■■■■■■■■■■■ 
MS8                    ◄■■■■■■■■►◄■■■■■■■►◄■■■■■■►   ◄■■■■■■■■■■■■■■■ 
 
 
061 gdvkltqsma iiryiadkhn mlggcpkera eismlegavl dirygvsria yskdfetlkv 
MS1                                                                   
MS2 ■■■►                                                              
MS3 ■■■►                                                              
MS4                                                                   
MS5 ■■■►                                                              
MS6 ■■■►                                                              
MS7 ■■■►◄■■■■■■■►                  ◄■■■■■■■■■■■■■■►                   
MS8 ■■■►◄■■■■■■■►                  ◄■■■■■■■■■■■■■■►                   
 
121 dflsklpeml kmfedrlchk tylngdhvth pdfmlydald vvlymdpmcl dafpklvcfk 
MS1                                                                   
MS2                                                                   
MS3                                                                   
MS4                                                                   
MS5                                                                   
MS6                                                                   
MS7                                                                   
MS8                                                                   
 
181 krieaipqid kylksskyia wplqgwqatf gggdhppksd liegrgipde lfplifpaep 
MS1                                                  ◄■■■■■■■■■■■■■■■ 
MS2                                                  ◄■■■■■■■■■■■■■■■ 
MS3                                                  ◄■■■■■■■■■■■■■■■ 
MS4   ◄■■■■■■■■►                                     ◄■■■■■■■■■■■■■■■ 
MS5   ◄■■■■■■■■►                                     ◄■■■■■■■■■■■■■■■ 
MS6  ◄■■■■■■■■■►                                     ◄■■■■■■■■■■■■■■■ 
MS7  ◄■■■■■■■■■►      ◄■■■■■■■■■■■■■■■■■■■■■►        ◄■■■■■■■■■■■■■■■ 
MS8  ◄■■■■■■■■■►      ◄■■■■■■■■■■■■■■■■■■■■■►  End of Data            
 
241 aqasgpyvei ieqpkqRgmr frykcegrsa gsipgeRstd ttkthptiki ngytgpgtvr 
MS1 ■■■■■■■■■■■■■■■►              ◄■■■■■■■■►             ◄■■■■■■■■■■► 
MS2 ■■■■■■■■■■■■■■■►              ◄■■■■■■■■►             ◄■■■■■■■■■■► 
MS3 ■■■■■■■■■■■■■■■►              ◄■■■■■■■■►             ◄■■■■■■■■■■► 
MS4 ■■■■■■■■■■■■■■■►              ◄■■■■■■■■►             ◄■■■■■■■■■■► 
MS5 ■■■■■■■■■■■■■■■►              ◄■■■■■■■■►             ◄■■■■■■■■■■► 
MS6 ■■■■■■■■■■■■■■■►              ◄■■■■■■■■►  End of Data             
MS7 ■■■■■■■■■■■■■■■►  End of Data                                     
 
301 islvtkdpph Rphphelvgk dcRdgfyeae lcpdrcihsf qnlgiqcvkk Rdleqaisqr 
MS1       ◄■■■■■■■■■■■■■►                                   ◄■■■■■■■► 
MS2       ◄■■■■■■■■■■■■■►                                   ◄■■■■■■■► 
MS3       ◄■■■■■■■■■■■■■►                                   ◄■■■■■■■► 
MS4       ◄■■■■■■■■■■■■■►                                   ◄■■■■■■■► 
MS5 End of Data                                                       
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361 iqtnnnpfqv pIeeqrgdyd lnavRlcfqv tvRdpsgRpl rlppvlshpi fdnrapntae 
MS1 ◄■■■■■■■■■■■■■■■►◄■■■■■■■■►         ◄■■■■■■■►◄■■■■■■■■■■■■►       
MS2 ◄■■■■■■■■■■■■■■■►◄■■■■■■■■►         ◄■■■■■■■►◄■■■■■■■■■■■■►       
MS3 ◄■■■■■■■■■■■■■■■►◄■■■■■■■■►         ◄■■■■■■■►◄■■■■■■■■■■■■►       
MS4 ◄■■■■■■■■■■■■■■■►                            ◄■■■■■■■■■■■■►       
 
421 lkicrvnrns gsclggdeif Llcdkvqked ievyftgpgw eargsfsqad vhrqvaivfR 
MS1                                                ◄■■■■■■■■■►◄■■■■■► 
MS2      ◄■■■■■■■■■►◄■■■■■■■■■■■■■■■■■■►◄■■■■■■■■■►◄■■■■■■■■■►◄■■■■■► 
MS3 End of Data                                                       
MS4 End of Data                                                       
 
481 tppyadpslq apvrvsmqlR RpsdRelsep mefqylpdtd drhRieekrk Rtyetfksim 
MS1 ◄■■■■■■■■■■■■■►            ◄■■■■■■■■■■■■■■■■■►  End of Data       
MS2 ◄■■■■■■■■■■■■■►            ◄■■■■■■■■■■■■■■■■■►  End of Data       
 
541 kkspfsgptd pRppprriav psrssasvpk papqpypfts slstinydef ptmvfpsgqi 
 
601 sqasalapap pqvlpqapap apapamvsal aqapapvpvL apgppqavap papkptqage 
 
661 gtlseallql qfddedlgal lgnstdpavf tdlasvdnse fqqllnqgIp vaphttepml 
 
721 meypeaItrL vtgaqRppdp apaplgapgl pngllsgded fssiadmdfs allsqiss 
 
 
 
 
Description: 
The measurements of the eight gel spots (see Figure 4.6) are named MS 1-8. The 
GST sequence is marked by a grey background. Aminoacids encoded by rare triplets 
(less than 1% of all codons for this AA) in E. coli are written white on black in bold 
capital letters. Smaller peptide fragments are marked with narrow bars. Longer, not 
completely digested fragments are marked with grey background. Very intense 
fragment signals are indicated by grey or black bars. 
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9.4 Sequence comparison of selected proteins between sus scrofa and homo 
sapiens 
9.4.1 RelA/p65 
 
Full name of human protein: v-rel reticuloendotheliosis viral 
oncogene homolog A (avian) (RELA), long transcript variant 
 
Identities = 515/553 (94%), Positives = 526/553 (96%), Gaps = 2/553 
(0%) 
 
homo s.   1 MDELFPLIFPAEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPT  60 
            MD+LFPLIFP+EPA ASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPT 
sus s.    1 MDDLFPLIFPSEPAPASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPT  60 
 
homo s.  61 IKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQC 120 
            IKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQC 
sus s.   61 IKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQC 120 
 
homo s. 121 VKKRDLEQAISQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPSGRPLRLPPVLS 180 
            VKKRDLEQAI+QRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDP+GRPLRLPPVLS 
sus s.  121 VKKRDLEQAINQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPAGRPLRLPPVLS 180 
 
homo s. 181 HPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFS 240 
            HPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFS 
sus s. 181  HPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFS 240 
 
homo s. 241 QADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEE 300 
            QADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEE 
sus s.  241 QADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEE 300 
 
homo s. 301 KRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINY 360 
            KRKRTYETFKSIMKKSPF+GPTDPRP  RRIAVPSRSSASVPKPAPQPYPFT SLSTIN+ 
sus s.  301 KRKRTYETFKSIMKKSPFNGPTDPRPATRRIAVPSRSSASVPKPAPQPYPFTPSLSTINF 360 
 
homo s. 361 DEFPTMVFPSGQI-SQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQ 419 
            DEF  M F SGQI  Q SALAPAP  VL QAPAPAPAPAM SALAQAPAPVPVLAPG  Q 
sus s.  361 DEFTPMAFASGQIPGQTSALAPAPAPVLVQAPAPAPAPAMASALAQAPAPVPVLAPGLAQ 420 
 
homo s. 420 AVAPPAPKPTQAGEGTLSEALLQLQFD-DEDLGALLGNSTDPAVFTDLASVDNSEFQQLL 478 
            AVAPPAPK  QAGEGTL+EALLQLQFD DEDLGALLGN+TDP VFTDLASVDNSEFQQLL 
sus s.  421 AVAPPAPKTNQAGEGTLTEALLQLQFDTDEDLGALLGNNTDPTVFTDLASVDNSEFQQLL 480 
 
homo s. 479 NQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIA 538 
            NQG+ + PHT EPMLMEYPEAITRLVTG+QRPPDPAP PLGA GL NGLLSGDEDFSSIA 
sus s.  481 NQGVSMPPHTAEPMLMEYPEAITRLVTGSQRPPDPAPTPLGASGLTNGLLSGDEDFSSIA 540 
 
homo s. 539 DMDFSALLSQISS  551 
            DMDFSALLSQISS 
sus s.  541 DMDFSALLSQISS  553 
 
Legend: 
NLS, + similar amino acid 
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9.4.2 HSP90AA1 
 
Full name of human protein: 
heat shock protein 90kDa alpha (cytosolic), class A member 1, short 
transcript 
 
Identities = 722/733 (99%), Positives = 726/733 (99%), Gaps = 1/733 
(0%) 
 
homo s.   1 MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIR  60 
            MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIR 
sus s.    1 MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIR  60 
 
homo s.  61 YESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFME 120 
            YESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFME 
sus s.   61 YESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFME 120 
 
homo s. 121 ALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPM 180 
            ALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPM 
sus s.  121 ALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPM 180 
 
homo s. 181 GRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKED 240 
            GRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKED 
sus s.  181 GRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKED 240 
 
homo s. 241 KEEEKEKEEKESEDKPEIEDVGSDEEEEKKDGDKKKKKKIKEK-YIDQEELNKTKPIWTR 299 
            KEEEKEKEEKESEDKPEIEDVGSDEEEE+K    KKKKK  ++ YIDQEELNKTKPIWTR 
sus s.  241 KEEEKEKEEKESEDKPEIEDVGSDEEEEEKKDGDKKKKKKIKEKYIDQEELNKTKPIWTR 300 
 
homo s. 300 NPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKN 359 
            NPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKN 
sus s.  301 NPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKN 360 
 
homo s. 360 NIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKK 419 
            NIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKK 
sus s.  361 NIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKK 420 
 
homo s. 420 CLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKD 479 
            CLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKD 
sus s.  421 CLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKD 480 
 
homo s. 480 YCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGK 539 
            YCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGK 
sus s.  481 YCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGK 540 
 
homo s. 540 TLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCI 599 
            TLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCI 
sus s.  541 TLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCI 600 
 
homo s. 600 VTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSV 659 
            VTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSV 
sus s.  601 VTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSV 660 
 
homo s. 660 KDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDTSAAVTEEMPPL 719 
            KDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADD+SAAVTEEMPPL 
sus s.  661 KDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDSSAAVTEEMPPL 720 
 
homo s. 720 EGDDDTSRMEEVD  732 
            EGDDDTSRMEEVD 
sus s.  721 EGDDDTSRMEEVD  733 
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9.5 Vector maps 
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